hpt training module oct 2010
TRANSCRIPT
© Ministry of Health, Malaysia 2010
First published 2010
Disease Control DivisionMinistry of Health, MalaysiaLevel 6, Block E10, Parcel EFederal Government Administration Centre62590 PUTRAJAYA
Tel: 03-8883 4145 Fax: 03-8888 6277
02.Layout 10/18/10 12:50 PM Page b
02.Layout 10/18/10 12:50 PM Page i
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
iiii
CHAIRPERSONDr. Abdul Rashid A. RahmanProfessor of Medicine & Clinical Pharmacologyand Senior Consultant Physician,Cyberjaya University College of MedicalSciences and An Nur Specialist Hospital,Selangor
SECRETARYDr. Sunita BavanandanConsultant Nephrologist,Kuala Lumpur Hospital,Kuala Lumpur
Dr. Anis Salwa KamaruddinPrincipal Assistant Director,Desease Control Division,Ministry of Health,Putrajaya
Dr. Chia Yook ChinProfessor of Primary Care Medicine and Senior Consultant Primary Care Physician,University Malaya Medical Centre,Kuala Lumpur
Dr. Fan Kin SingConsultant Nephrologist,Gleanagles Intan Medical Centre,Kuala Lumpur
Dr. Ghazali AhmadConsultant Nephrologist and Head of Department,Department of Nephrology,Kuala Lumpur Hospital,Kuala Lumpur
Dr. Khoo Ee MingProfessor of Primary Care Medicine andSenior Consultant Primary Care Physician,University Malaya Medical Centre,Kuala Lumpur
Dr. Khalid YusoffProfessor of Medicine and Senior Consultant CardiologistUniversity Technology MARA, Selangor
Dr. Robaayah ZambahariSenior Consultant Cardiologist,National Heart Institute,Kuala Lumpur
Dr. Zaleha Abdullah MahdyProfessor and Senior Consultant Obstetrician& Gynaecologist,Hospital Universiti Kebangsaan Malaysia,Kuala Lumpur
Dr. Hj. Azhari RosmanConsultant Cardiologist & Electrophysiologist,National Heart Institute,Kuala Lumpur
Dr. Chua Chin TeongConsultant Nephrologist,Selangor
Dr. Faridah Aryani Md. YusofClinical Trial Pharmacist andPharmacoeconomist,Clinical Research Centre,Kuala Lumpur Hospital,Kuala Lumpur
Dr. Guna SegaranConsultant Obstetrician and Gynaecologist,Damansara Specialist Hospital,Selangor
Dr. Khoo Kah LimConsultant Cardiologist,Pantai Medical Centre,Kuala Lumpur
Dr. Lim Yam NgoConsultant Paediatric Nephorologist,Kuala Lumpur Hospital,Kuala Lumpur
Dr. Yap Piang KianConsultant Physician & Endocrinologist,Subang Jaya Medical Centre,Selangor
HYPERTENSION GUIDELINEWORKING GROUP
HY
PE
RTE
NS
ION
GU
IDE
LIN
EW
OR
KIN
GG
RO
UP
02.Layout 10/18/10 12:50 PM Page ii
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
iii
Associate Professor Dr. Anis Safura RamliConsultant Family Medicine Specialist,Head of Primary Care Medicine Discipline,Faculty of Medicine,Universiti Teknologi MARA (UiTM),Sungai Buloh Campus
Dr. Ng. Kien KeatSenior Lecturer & Family Medicine Specialist,Primary Care Medicine Discipline, Faculty of Medicine,Universiti Teknologi MARA (UiTM),Sungai Buloh Campus
Dr. Mastura IsmailConsultant Family Medicine Specialist,Klinik Kesihatan Seremban 2, Negeri Sembilan
Dr. Feisul Idzwan MustaphaPublic Heath Specialist and Senior Principal Assistant Director,Disease Control Division, Ministry of Health, Malaysia
Dr. Norhayati Ab. ShatarMedical Officer,Principal Assistant Director,Disease Control Division, Ministry of Health, Malaysia
EDITORS
Professor Dr. Teng Cheong LiengSenior Consultant Family Medicine Specialist,International Medical University (IMU), Bukit Jalil
Associate Professor Dr. Tong Seng FahConsultant Family Medicine Specialist,Universiti Kebangsaan Malaysia (UKM), Bangi
Associate Professor Dr. Anis Safura RamliConsultant Family Medicine Specialist,Universiti Teknologi Mara (UiTM), Sungai Buloh
Dr. Mastura IsmailConsultant Family Medicine Specialist, Klinik Kesihatan Seremban 2, Negeri Sembilan
Dr. Suhazeli AbdullahConsultant Family Medicine Specialist,Klinik Kesihatan Marang, Terengganu
Dr. Verna Lee Kar MunSenior Lecturer & Family Medicine Specialist, International Medical University (IMU), Bukit Jalil
Dr. Chew Boon HowSenior Lecturer & Family Medicine Specialist,Universiti Putra Malaysia (UPM), Serdang
Dr. Ambigga Devi S. KrishnapillaiSenior Lecturer & Family Medicine Specialist, Universiti Teknologi Mara (UiTM), Sungai Buloh
Dr. Maizatullifah MiskanSenior Lecturer & Family Medicine Specialist, Universiti Teknologi Mara (UiTM), Sungai Buloh
Dr. Ng Kien KeatSenior Lecturer & Family Medicine Specialist, Universiti Teknologi Mara (UiTM), Sungai Buloh
Dr. Mazapuspavina Md. YasinSenior Lecturer & Family Medicine Specialist, Universiti Teknologi Mara (UiTM), Sungai Buloh
Dr. Farnaza AriffinSenior Lecturer & Family Medicine Specialist, Universiti Teknologi Mara (UiTM), Sungai Buloh
Dr. Nafiza Mat NasirSenior Lecturer & Family Medicine Specialist, Universiti Teknologi Mara (UiTM), Sungai Buloh
CONTRIBUTORS
ED
ITO
RS
&C
ON
TRIB
UTO
RS
02.Layout 10/18/10 12:50 PM Page iii
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
iv
TABLE OF CONTENTSHypertension Guideline Working Group ii
Editors & Contributors iii
Introduction v
Topic 1 Introduction & Overview of Hypertension Burden in Malaysia 1
Topic 2 Diagnosis and Management of Pre-hypertension 21
Topic 3 Diagnosis and Management of Stage 1 Hypertension 31
Topic 4 Diagnosis and Management of Stage 2 Hypertension & 43Resistant Hypertension
Topic 5 Diagnosis and Management of Stage 3 Hypertension 53
Topic 6 Hypertension and Diabetes 63
Topic 7 Hypertension and Metabolic Syndrome 73
Topic 8 Hypertension and Cardiovascular Disease 79
Topic 9 Hypertension and Stroke 87
Topic 10 Hypertension in the Elderly 101
Topic 11 Hypertension in Pregnancy 107
Topic 12 Hypertension and Oral Contraceptive Pills 117
Topic 13 Hypertension and Hormone Replacement Therapy 121
Topic 14 Workshop on Blood Pressure Measurement 129(Techniques & Skills)
Appendix Pre-test and Post-test questionnaires (MCQs) 135
TAB
LEO
FC
ON
TEN
TS
02.Layout 10/18/10 12:50 PM Page iv
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
v
INTRODUCTIONThe Clinical Practice Guidelines (CPG) on the Management of Hypertension (3rd Edition) waspublished in February 2008 and the Quick Reference (QR) for Health Care Providers was publishedin January 2010.
OBJECTIVE
This Training Module is developed to assist the ‘trainers’ to:1. Deliver the key content and messages of the CPG systematically.2. Demonstrate the applicability of CPG recommendations in clinical practice via interactive case
discussions.3. Offer implementation strategies for effective hypertension management based on key elements
of the Wagner Chronic Care Model.
This document contains the following:1. CD-ROM containing the powerpoint presentations.2. Introduction and summary of training module content.3. Interactive case discussions in the beginning of each topic.4. Pre-test and post-test questionnaire (MCQs).5. Evaluation feedback of the training session.
Target Audience:All levels of health care providers involved with the care of hypertensive patients in both primarycare and secondary care settings.
Clinical QuestionsIn tandem with the main CPG, the clinical questions to be addressed in this training module include:1. What are the current best practices in the management of a patient with hypertension?2. How can hypertension management be done in tandem with the overall strategy to manage
global vascular risk of a patient?3. How can we improve the outcome of care for hypertensive patients?
Key Recommendations for Successful Implementation of this TrainingModule:1. Use interactive group discussion methods, rather than didactic way of teaching.2. Gauge the learning and language used (English/Malay/Others) to the level of target audience
(suited to various levels of health care providers).3. Use problem-based facilitating methods.4. Encourage participants to familiarize themselves with the CPG and the QR prior to the training
session (prerequisite).5. Emphasize teamwork.6. Allow participants to express their ideas, concerns and expectations openly.7. Address issues constructively.8. Obtain systematic feedback from participants.
INTR
OD
UC
TIO
N
02.Layout 10/18/10 12:50 PM Page v
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
vi
Key implementation strategies to improve outcome for patients withchronic conditions in primary care (Adapted from the Wagner Chronic CareModel and WHO Innovative Care for Chronic Conditions Framework):
Delivery system • Redesign the delivery system using MESO LEVEL* redesign multidisciplinary care teams, supported by • District Health Office
mutually understood care plan and • Primary Health Care pathways.* Team
• Define roles and tasks among team members.*
• Stratify patients by risks and provide case management for those who are most at risk.*
• Involve secondary care specialists and create mutually agreed shared care plans for patients with severe complications and end-stage disease.*
Clinical information • Develop national# and local chronic disease MACRO LEVEL#
systems registries.* • Policy makers• Use electronic medical record and
appointment system.* MESO LEVEL*• Use electronic prescribing, reminder and • Primary Health Care
alerts on potential drug interaction and test Team results.*
• Create paper-based registries and MICRO LEVEL*comprehensive medical records in resource- • Individual doctors and limited setting.* allied health care
providers
Decision support • Embed evidence-based clinical guidelines MESO LEVEL*recommendations into the structure of • Primary Health Care day-to-day decision-making process e.g. Team electronic reminders, academic detailing, etc.* MICRO LEVEL*
• Make patients aware of the evidence- • Individual doctors and based guidelines recommendations e.g. allied health care treatment targets, choice of therapy, etc.* providers
Patient self- • Empower patients and their families with MESO LEVEL*management knowledge, skills and confidence to take • Primary Health Care support effective control over their chronic Team
• Provide self-management tools, and routinely assess problems and MICRO LEVEL* accomplishments.* • Individual doctors and
• Establish ongoing collaborative effort allied health care between care team and patients for providerslong term benefit.* • Patients and families
Key Elements Implementation Strategies Level of actions
INTR
OD
UC
TIO
N
02.Layout 10/18/10 12:50 PM Page vi
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
vii
Healthcare • Become the agent of change to transform ALL LEVELS@
organization chronic disease care.@
involvement • Restructure health care system and policy MACRO LEVEL#
with a clear focus to improve chronic • Policy makers disease care.#
• Create universal funding mechanism to MESO LEVEL*improve access and equity.# • Primary Health Care
• Provide incentives for achieving clinical Team targets, enhancing preventive care, or otherquality improvement activities.#
• Perform ongoing clinical audit as part ofquality assurance programme to improvechronic care quality.*
Community • Develop link with community resources MESO LEVEL* resources which provide self-management support • Primary Health Care
e.g. self-help groups, non-governmental Team organizations, etc.*
MICRO LEVEL*• Individual doctors and
allied health care providers
• Patients and families
Key Elements Implementation Strategies Level of actions
INTR
OD
UC
TIO
N
02.Layout 10/18/10 12:50 PM Page vii
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
viii
No
Summary of Training Module Content
Topic Objective ContentTeachingLearningMethod
Duration(minutes)
1. Introduction • To provide an overview of • Epidemiology of Hypertension Lecture 60& Overview HPT burden in Malaysia • Definition and classification of (45 minutes of CPG on • To provide the knowledge hypertension introductoryHypertension based regarding definition, • Measurement of blood pressure lecture + Management diagnosis, assessment, • Diagnosis and assessment 15 minutes
CV risk stratification and • Cardiovascular risk stratification Q&A) management of HPT • Algorithm for the management of
• To offer implementation hypertension strategies for effective • Lifestyle modification advicehypertension management • Pharmacological Agents based on key elements of • The Wagner Chronic Care Model the Wagner Chronic Care • Roles and responsibilities of Mode multidisciplinary care team in
managing hypertension• Roles and responsibilities of
patients in self-managing hypertension
• Key messages
2. Diagnosis and • To highlight the importance • Case scenario 1 Interactive 60management of opportunistic screening • Management based on CPG case (45 minutesof Pre- for Pre-hypertension recommendation discussion interactivehypertension • To highlight the importance • Summary of evidence for the discussion +
of therapeutic lifestyle recommendation 15 minutesmodification in the • Key messages Q&A)management ofPre-hypertension
3. Diagnosis and • To highlight the importance • Case scenario 2 Interactive 60 management of opportunistic screening • Management based on CPG case (45 minutes of Stage 1 of blood pressure recommendation discussion interactiveHypertension • To highlight the importance • Summary of evidence for the discussion +
of performing CV risk in recommendation 15 minutes guiding treatment • Key messages Q&A)
4. Diagnosis and • To highlight the importance • Case scenario 3 Interactive 60management of combination treatment • Management based on CPG case (45 minutesof Stage 2 in the management of recommendation discussion interactiveHypertension Stage 2 Hypertension • Summary of evidence for the discussion + and Resistant • To highlight the importance recommendation 15 minutes Hypertension of identifying resistant • Key messages Q&A)
hypertension
5. Diagnosis and • To highlight the importance • Case scenario 4 Interactive 60management of hypertensive urgencies • Management based on CPG case (45 minutesof Stage 3 and emergencies recommendation discussion interactiveHypertension • To highlight the importance • Summary of evidence for the discussion +
of assessing for target organ recommendation 15 minutesdamages/complications • Key messages Q&A)
INTR
OD
UC
TIO
N
02.Layout 10/18/10 12:50 PM Page viii
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
ix
No Topic Objective ContentTeachingLearningMethod
Duration(minutes)
6. Hypertension • To highlight the importance • Case scenario 5 Interactive 60and Diabetes of aggressive BP control in • Management based on CPG case (45 minutes Mellitus Diabetes recommendation discussion interactive
• To highlight the appropriate • Summary of evidence for the discussion + choice of pharmacological recommendation 15 minutestreatment according to • Key messages Q&A)current evidence
7. Hypertension • To highlight the importance • Case scenario 6 Interactive 60 and Metabolic of diagnosing MetS • Management based on CPG case (45 minutesSyndrome • To highlight the importance recommendation discussion interactive (MetS) of treating HPT in MetS • Summary of evidence for the discussion +
recommendation 15 minutes• Key messages Q&A)
8. Hypertension • To appreciate HPT as a • Case scenario 7 Interactive 60and major risk factor to many • Management based on CPG case (45 minutesCardiovascular cardiovascular diseases recommendation discussion interactiveDisease • To make an appropriate • Summary of evidence for the discussion +
choice of recommendation 15 minutesanti-hypertensive • Key messages Q&A)medication in patientswith concomitant cardiovascular disease
• To be aware of the targets for treatment
9. Hypertension • To highlight the danger of • Case scenario 8 Interactive 60 and Stroke rapid reduction of BP in • Management based on CPG case (45 minutes
patients with acute stroke recommendation discussion interactive• To highlight the appropriate • Summary of evidence for the discussion +
choice of pharmacological recommendation 15 minutestreatment according to • Key messages Q&A)current evidence
10. Hypertension • To highlight the importance • Case scenario 9 Interactive 60in the Elderly of treating systolic • Management based on CPG case (45 minutes
HPT in elderly recommendation discussion interactive• To address the issues of • Summary of evidence for the discussion +
polypharmacy in elderly recommendation 15 minutes• Key messages Q&A)
11. Hypertension • To highlight the • Case scenario 10 Interactive 60in Pregnancy classifications of • Summary of evidence for the case (45 minutes
Hypertension in Pregnancy recommendation discussion interactive• To highlight the importance • Summary of evidence for the discussion +
of identifying those at risks recommendation 15 minutes of developing Hypertension • Key messages Q&A)in Pregnancy
INTR
OD
UC
TIO
N
02.Layout 10/18/10 12:50 PM Page ix
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
x
Topic Objective ContentTeachingLearningMethod
Duration(minutes)
12. Hypertension • To highlight the important • Case scenario 11 Interactive 60and Oral interaction between BP • Management based on CPG case (45 minutesContraceptive and OCP recommendation discussion interactivePills • Summary of evidence for the discussion +
recommendation 15 minutes• Key messages Q&A)
13. Hypertension • To highlight the important • Case scenario 12 Interactive 60and Hormone interaction between BP • Management based on CPG case (45 minutesReplacement and HRT recommendation discussion interactiveTherapy • Summary of evidence for the discussion +
recommendation 15 minutes• Key messages Q&A)
14. Workshop on • To demonstrate accurate • Hands-on skills training Workshop 5 60BP techniques of BP Lecture:measurement measurements Lecture 20 minutes(technique followed by Hands-on:and skills) hands-on 40 minutes
training
15. Assessment • To test the knowledge of • 15 T/F MCQs Pre-test and 60of knowledge participants pre and post • 15 Single Best Answer (SBA) post test
training Questions questionnaire
INTR
OD
UC
TIO
N
02.Layout 10/18/10 12:50 PM Page x
02.Layout 10/18/10 12:50 PM Page 1
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
2
Slide 1
PRESENTATION OUTLINE
• Epidemiology of Hypertension• Definition • Measurement of Blood Pressure• Diagnosis & Classification• Evaluation & Assessment • Management Algorithm• Cardiovascular Risks Stratification• Therapeutic Lifestyle Modification• Pharmacological Agents• The Wagner Chronic Care Model• Key messages
Slide 2
GLOBAL BURDEN FOR HYPERTENSION
An Estimated 972 million individuals worldwide suffer from hypertension in the year 2000.Kearney et al.
Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365 (9455):217-23
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 2
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
3
Slide 3
THE RISING EPIDEMIC OF HYPERTENSION
National Health Morbidity Surveys I, II & III (1986-2006)
Slide 4
NHMS III : AWARENESS RATE
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 3
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
4
Slide 5
NHMS III : TREATMENT RATES
Slide 6
NHMS III : CONTROLLED RATE
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 4
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
5
Slide 7
DEFINITION
Hypertension is defined as persistent elevation of systolic BP of 140 mmHg or greaterand/or diastolic BP of 90 mmHg or greater.
Slide 8
INITIAL ASSESSMENT
Slide 9
DIAGNOSIS & CLASSIFICATION
Initial BP (mmHg)
Systolic Diastolic
Follow-up recommended to confirm diagnosis and/orreview response to treatment.
< 130 and < 85
130-139 and 85-89
140-159 and/or 90-99
160-179 and/or 100-109
180-209 and/or 110-119
Recheck in one year
Recheck within 3-6 months
Confirm within two months and treat if medium, high or veryhigh risks
Evaluate within one month and treat when confirmed
Look for symptoms and sign of hypertensive urgency oremergency, if asymptomatic, evaluate within one week andtreat whan confirmed
≥ 210 and/or ≥ 120 Initiate drug treatment immediately
Optimal
Prehypertension
Stage 1 HPT
Stage 2 HPT
Stage 3 HPT
< 120
120-139
140-159
160-179
≥ 180
and
and/or
and/or
and/or
and/or
< 80
80-89
90-99
100-109
≥ 110
Diagnosis ofhypertension ismade based on theaverage of two ormore readings,taken at two ormore visits to thehealth careproviders
Category Systolic (mmHg) Diastolic (mmHg)IN
TRO
DU
CTI
ON
&O
VE
RV
IEW
OF
HP
TB
UR
DE
NIN
MA
LAY
SIA
02.Layout 10/18/10 12:50 PM Page 5
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
6
Slide 10
EVALUATION
EVALUATION OF NEWLY DIAGNOSED HYPERTENSIVE PATIENTS
Evaluation should include through history, physical examination and relevantinvestigations.
Three main objectives:
1. To exclude secondary causes of hypertension
2. To ascertain the presence of target organ damage (TOD)
3. To assess lifestyle and identity other cardiovascular risk factors and/or concomitant disorders that may affect treatment and prognosis.
Slide 11
MEDICAL HISTORY
• duration and level of elevated BP if known• symptoms of secondary causes of hypertension• symptoms of target organ damage, e.g. coronary heart disease (CHD) and
cerebrovascular disease• symptoms of concomitant disease that will affect prognosis or treatment, e.g. diabetes
mellitus, renal disease and gout• family history of hypertension, CHD, stroke, diabetes, renal disease or dyslipidaemia• dietary history including salt, fat, caffeine and alcohol intake• drug history of either prescribed or over-the-counter medication (NSAIDS, nasal
decongestants) and herbal treatment• lifestyle and environmental factors that will affect treatment and outcome, e.g.
smoking, physical activity, work stress and excessive weight gain since childhood
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 6
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
7
Slide 12
PHYSICAL EXAMINATIONS
• general examination: height, weight and waist circumference• two or more BP measurements separated by two minutes with the patient either supine
or seated; and after standing for at least one minute• measure BP on both arms• fundoscopy• look for carotid bruit, abdominal bruit, presence of peripheral pulses and radio-femoral
delay• cardiac examination• chest examination for evidence of cardiac failure• abdominal examination for renal masses, aortic aneurysm and abdominal obesity• neurological examination to look for evidence of stroke• signs of endocrine disorders, e.g. Cushing syndrome, acromegaly and thyroid disease
Slide 13BASELINE INVESTIGATIONS
• Full blood count• Urinalysis• Urine albumin excretion or albumin/creatinine ratio• Renal profile and serum uric acid• Fasting blood sugar• Fasting lipid profile• Electrocardiogram (ECG)• Chest X-ray (if clinically indicated)
Note : Should be repeated 6-12 monthly thereafter (except for Chest X-Ray)
Slide 14
CARDIOVASCULAR RISK FACTORS
• Hypertension• Cigarette smoking• Central obesity (waist circumference > 90 cm for men, > 80 cm for women)• Physical inactivity• Dyslipidaemia• Diabetes mellitus• Microalbuminuria• Estimated GFR < 60 mL/min• Age (> 55 years for men, > 65 years for women)• Family history of premature cardiovascular disease (men < 55 years or women < 65 years)
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 7
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
8
Slide 15
SECONDARY CAUSES
• Sleep apnoea• Drug-induced or drug-related• Chronic kidney disease• Primary aldosteronism• Renovascular disease• Chronic steroid therapy and Cushing syndrome• Phaeochromocytoma• Acromegaly• Thyroid or parathyroid disease• Coarctation of the aorta• Takayasu Arteritis
Slide 16
TARGET ORGAN DAMAGE & COMPLICATIONS
MANIFESTATIONS OF TOD/TARGET ORGAN COMPLICATION (TOC)
Cardiac
Cerebrovascular
Peripheralvasculature
Renal
Retinopathy
Organ System Manifestations
Left ventricular hypertrophy (LVH), coronary heart disease (CHD),heart failure
Transient ischaemic attack (TIA), stroke
Absence of one or more major pulses in extremities (exceptdorsalis pedis) with or without intermittent claudication
GFR < 60ml/min/1.73m2, proteinuria (≥1+), microalbuminuria (2 outof 3 positive tests over a period of 4-6 months)
Haemorrhages or exudates, with or without papilloedema
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 8
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
9
Slide 17
ALGORITHM FOR THE MANAGEMENT OF HYPERTENSION
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 9
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
10
Slide 18
CARDIOVASCULAR RISK STRATIFICATION
Co-existingCondition
BP Levels(mmHg)
SBP 120-139and/or
DBP 80-89Low Medium High Very High
SBP 140-159 and/or
DBP 90-99Low Medium High Very High
SBP 160-179 and/or
DBP 100-109Medium High Very High Very High
SBP 180-209 and/or
DBP 100-119High High Very High Very High
SBP ≥ 210 and/or
DBP ≥ 120Very High Very High Very High Very High
No RFNo TODNo TOC
TOD orRF (1-2),No TOC
TOD or RF (≥ 3) or Clinicalatherosclerosis
Previous MI orPrevious Stroke
or DiabetesMellitus (DM)
Risk Level Risk of major CV event in 10 years Management
Low < 10% Lifestyle changes
Medium 10-20% Drug treatment and lifestylechanges
High 20-30% Drug treatment and lifestylechanges
Very High > 30% Drug treatment and lifestylechanges
TOD : LVH, Retinopathy, Proteinuria / TOC : Heart Failure, Renal Failure)Risk Factors (RF): additional RF (smoking, TC > 6.5 mmol/L, family history of premature vascular disease) Clinicalatherosclerosis (CHD, carotid stenosis, peripheral vascular disease, TIA, stroke)MI: Mycardial Infarction
Green Yellow Orange RedLegend:
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 10
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
11
Slide 19
BLOOD PRESSURE TREATMENT TARGETS
Category Target blood pressure (mmHg)
Uncomplicated hypertension < 140/90
Hypertension in high risk groups: DM, History of CVD < 130/80
Diabetics with proteinuria of > 1g/24 hours < 125/75
Once target BP is achieved, follow-up at 3-6 month interval is appropriate.
Slide 20
THERAPEUTIC LIFESTYLE MODIFICATION
Therapeutic lifestyle modification is the first line treatment in all patientswith hypertension.
Weightreduction
As far as possible aim for an ideal Body Mass Index [Weight(kg)/Height2 (m)] – for Asians, the normal range has been proposedto be 18.5 to 23.5 kg/m2. However a weight loss as little as 4.5 kgsignificantly reduces BP
Salt intake
An intake of < 100 mmol of sodium or 6g of sodium chloride aday is recommended (equivalent to < 1 1/4 teaspoonfuls of salt or3 teaspoonfuls of monosodium glutamate)
Alcohol intake
Standard advice is to restrict intake to no more than 21 units formen and 14 units for women per week (1 unit equivalent to 1/2 apint of beer or 100 ml of wine or 20 ml of proof whisky)
Physical activity
General advice on cardiovascular health would be for “milder”exercise, such as brisk walking for 30 – 60 minutes at least 3times a week
DietA diet rich in fruits, vegetables and dairy products with reducedsaturated and total fat can substantially lower BP (11/6 mmHg inhypertensive patients and 4/2 mmHg in patients with high normalBP)
Smoking cessation Cessation of smoking is important in the overall management of
the patients with hypertension in reducing cardiovascular risk
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 11
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
12
Slide 21
ANTIHYPERTENSIVE AGENTS
Formulation Minimumdose
Maximumdose Remarks
Diuretics
Chlorothiazide 250 mg OD 500 mg OD • Potassium should be closely Hydrochlorothiazide 25 mg OD 200 mg OD monitored.Amiloride/hydrochlorothiazide 1 tablet OD 4 tablet OD • Used with care in patient with gout.
5mg/50mgIndapamide SR 1.5 mg OD 1.5 mg OD • Potassium sparing diuretics may Indapamide 2.5 mg OD 2.5 mg OD cause hyperkalemia if given withTriamterene/hydrochlorothiazide 1 tablet BD 2 tablet BD ACEIs/ARBs/renal insufficiency.
50mg/25mg
ß-blockers
Atenolol 50 mg OD 100 mg OD • Contraindicated in patient with Bisoprolol 5 mg OD 10 mg OD COAD, severe Peripheral Metoprolol 50 mg BD 200 mg BD Vascular Disease and heart Propranolol 40 mg BD 320 mg BD block.
Calcium Channel Blockers (CCBs)
Amlodipine 5 mg OD 10 mg OD • Verapamil may reduce heart rate Diltiazem 30 mg TDS 60 mg TDS and use with care with ß-blockersDiltiazem SR 90 mg BD 90 mg BDFelodipine 2.5 mg OD 10 mg ODLercanidipine 10 mg OD 20 mg ODNifedipine 10 mg TDS 30 mg TDSNifedine SR 30 mg OD 120 mg ODVerapamil 80 mg BD 240 mg TDSVerapamil CR 200 mg OD 200 mg BD
ACE Inhibitors (ACEIs)
Captopril 25 mg BD 50 mg TDS • Contraindicated in pregnancy and Enalapril 2.5 mg OD 20 mg BD bilateral renal artery stenosisLisinopril 5 mg OD 80 mg OD • Check serum creatinine before Perindopril 2 mg OD 8 mg OD initiation and repeat 2 weeks after Ramipril 2.5 mg OD 10 mg OD initiationQuinapril 2.5 mg OD 40 mg BD • ACEIs should be stopped if rise in
creatinine > 30% from baseline
Angiotensin Receptor Blockers (ARBs)
Candesartan 8 mg OD 16 mg OD • Contraindicated in pregnancy and Irbesartan 150 mg OD 300 mg OD bilateral renal artery stenosisLosartan 50 mg OD 100 mg ODTelmisartan 20 mg OD 80 mg ODValsartan 80 mg OD 160 mg ODOlmesartan 20 mg OD 40 mg OD
Miscellaneous
Prazosin (α-blocker) 0.5 mg BD 10 mg BD • Doxazosin is useful in patientDoxazosin 1 mg OD 16 mg OD with benign prostatic hypertrophyLabetalol 100 mg BD 800 mg TDS • In elderly, start Labetolol with Carvedilol 12.5 mg OD 50 mg OD 50mg BDMethyldopa 125 mg BD 1 gm BD
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 12
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
13
Slide 22
PHARMACOLOGICAL MANAGEMENT OF STAGE 1 HYPERTENSION
Slide 23
CHOICE OF FIRST LINE MONOTHERAPY
In patients with newly diagnosed uncomplicated hypertension who have no compellingindications, choice of first line monotherapy includes ACEIs, ARBs, CCBs and Diuretics.
β-blockers are no longer recommended for first line monotherapy in this group ofpatients.
However, it may be considered in younger people, particularly those who are intolerant orcontraindicated to ACEI or ARB, women of child bearing potential and patients withevidence of increased sympathetic drive.
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 13
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
14
Slide 24
PHARMACOLOGICAL MANAGEMENT OF STAGE 2 HYPERTENSIONInitiating therapy with the right combination of at least 2 drugs isrecommended.
EFFECTIVE ANTIHYPERTENSIVE COMBINATION
Effective combination Comments
ß-blockers + diuretics Benefits proven in the elderly, cost-effective. However, may increase the risk of new onset diabetes
ß-blockers + CCBs Relatively cheap, appropriate for concurrent CHD
CCBs + ACEls/ARBs Appropriate for concurrent dysliplidaemias and diabetes mellitus
ACEls + diuretics Appropriate for concurrent heart failure, diabetes mellitus and stroke
ARBs + diuretics Appropriate for concurrent heart failure and diabetes mellitus
Slide 25
CHOICE OF HYPERTENSIVE AGENTS IN PATIENTS WITH CONCOMITANTCONDITIONS
Diabetes mellitus (without nephropathy) + +/- +++ + +/- ++
Diabetes mellitus (with nephropathy) ++ +/- +++ ++* +/- +++
Gout +/- + + + + +
Dyslipidaemia +/- +/- + + + +
Coronary heart disease + +++ +++ ++ + ++
Heart failure +++ +++# +++ +@ + +++
Asthma + - + + + +
Peripheral vascular disease + +/- + + + +
Non-diabetic renal impairment ++ + +++ +* + ++
Renal artery stenosis + + ++$ + + ++$
Elderly with no co-morbid conditions +++ + + +++ +/- +
Very elderly (> 80 years old) with no +++ + ++ + +/- +co-morbid conditions
Concomitant disease Diuretics ß-blockers ACEIs CCBs Peripheral α-blockers ARBs
The grading of recommendation from (+) to (+++) is based on increasing levels of evidence and/or current widely accepted practice+/- Use with care- Contraindicated* Only non-dihydropyridine CCB# Metoprolol, bisoprolol, carvedilol – dose needs to be gradually titrated@ Current evidence available for amlodipine and felodipine only$ Contraindicated in bilateral renal artery stenosis
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 14
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
15
Slide 26
RESISTANT HYPERTENSION
If BP is still > 140/90 mmHg with combination of 3 drugs (including a diuretic at nearmaximal doses) - check on the possible causes of resistant HPT:• Non-compliance• Secondary hypertension• White coat hypertension• Excessive salt or liquorice intake• Drug interaction• Complications of long standing hypertension e.g nephrosclerosis, loss of aortic
distensibility and atherosclerotic renal artery stenosis
Slide 27
SEVERE HYPERTENSION
Severe hypertension is defined as BP > 180/110mm Hg(persistent elevation after 30 minutes bed rest)
Asymptomatic severeHPT• Incidental findings• Non-specific
symptoms likeheadache, dizziness,lethargy
Management• Most can be
managed asoutpatient
• Review existing drugregime andcompliance
• For newly-diagnosed,consider admissionfor evaluation
• For established HPT,admit if complianceremains a problem
Hypertensiveurgencies• Presents with grade III
or IV retinal changes,or proteinuria ≥ 2+,but no overt organfailure
Management• Initial treatment
should aim for 25%reduction in BP over24 hours but notlower than 160/90mmHg
• Combination therapyis often necessary(see table below)
• Admit patient if BPremain > 180/110mmHg
Hypertensiveemergencies• Presents with
symptoms and signsof TOC e.g. acuteheart failure,subarachnoidhaemorrhage, acutecoronary syndromes
Management • All patient should be
admitted• Aim to reduce BP by
25% over 3-12 hoursbut not lower than160/90 mmHg
• Best achieved withparenteral drugs
Possible clinical scenarios
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 15
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
16
Slide 28
THE CHRONIC CARE MODEL
Slide 29
6 ELEMENT OF CHRONIC CARE MODEL
No. Elements Explanation
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
1. Health care Create policies with a clear focus to improve chronic disease care.organization Goals, values & incentives to care providers must be aligned & policies with payers & MOH
2. Community Patients & care providers need linkages with community resources resources such as home care, exercise program and support
groups
3. Self Empower patients with knowledge and skills to enhance management confidence to self-care. Build quality relationship throughsupport effective communication
4. Delivery system Multi-disciplinary practice team with clear division of labour; redesign planned management and visits
5. Decision support Translate evidence based clinical practice guidelinerecommendations into daily clinical practice and improve access to specialist expertise
6. Clinical Computerized system to remind & prompt actions; support information shared care among multiple professionals, provide feedback to system health care personel and track progress
02.Layout 10/18/10 12:50 PM Page 16
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
17
Slide 30
Multi DisciplinaryTeam Members
Roles and Responsibilities
Doctors • Lead the multidisciplinary team• Negotiate and create care pathways to work with other members
of the team• Perform a complete history and physical examination• Review investigation results• Ascertain the presence or absence of TOD/TOC• Identify other CV risk factors and/or concomitant disorders that
affect treatment and prognosis• Assess global CV risks for individual patient• Exclude secondary causes of HPT in suspected cases• Explain to patient regarding achievement of control targets • Make therapeutic decisions• Emphasize the advice given by other allied team members• Assess and address patient’s ideas, concerns and expectations• Offer psychosocial support where appropriate
Slide 31
Multi DisciplinaryTeam Members
Roles and Responsibilities
Nurses • Conduct anthropometric measurements• Coordinate baseline/ relevant investigations• Assess lifestyle – diet, exercise and smoking status• Educate patient regarding hypertension, cardiovascular risks and
potential complications• Educate patient regarding control targets • Counsel patient regarding therapeutic lifestyle modification• Arrange follow-up as per care pathway• Track and remind defaulters• Assess and address patient’s ideas, concerns and expectations• Offer psychosocial support where appropriate
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 17
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
18
Slide 32
Multi DisciplinaryTeam Members
Roles and Responsibilities
MA • Conduct anthropometric measurements• Coordinate baseline/ relevant investigations as agreed in the care
pathway• Assess lifestyle – diet, exercise and smoking status• Continue drug treatment if BP controlled• Discuss with doctor if BP not controlled• Educate patient regarding hypertension, cardiovascular risks and
potential complications• Educate patient regarding control targets • Counsel patient regarding therapeutic lifestyle modification• Arrange follow-up as per care pathway• Track and remind defaulters• Assess and address patient’s ideas, concerns and expectations• Offer psychosocial support where appropriate
Slide 33
Multi DisciplinaryTeam Members
Roles and Responsibilities
Pharmacists
Dieticians
• Educate patient regarding antihypertensive medication, itspotential benefits and side effects
• Monitor side-effects• Assess adherence to medication• Assess and address patient’s ideas, concerns and expectations of
the medications
• Perform detail dietary assessment• Educate patient regarding calorie intake• Counsel regarding healthy dietary habit• Counsel regarding weight management where appropriate• Assess and address patient’s ideas, concerns and expectations
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 18
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
19
Slide 34
KEY LEARNING POINTS
• Hypertension (HPT) is defined as persistant elevations of SBP of ≥ 140mmHg and/orDBP ≥ 90 mmHg
• In 2006, prevalence of HPT in Malaysia was 42.6% among those aged ≥ 30 years• HPT is a silent disease; 64% of cases remain undiagnosed. Therefore, BP should be
measured at every chance encounter• Untreated or sub-optimally controlled HPT leads to increased cardiovascular,
cerebrovascular and renal morbidity and mortality• A SBP of 120-139 and/or DBP of 80-90mm Hg is defined as pre-HPT and should be
treated in certain high risk groups• Therapeutics lifestyle changes should be recommended for all individuals with HPT and
pre-HPT• Decision to commence pharmacological treatment should be based on global
cardiovascular risks and not on the level of blood pressure (BP) per se• In patients with newly diagnosed uncomplicated HPT who have no compelling
indications, choice of first line monotherapy includes ACEIs, ARBs, CCBs and Diuretics.ß-blockers are no longer recommended as first line monotherapy
• Only 26% of treated patients achieve target BP• Combination therapy is often required ti achieve target and may be instituted early
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
Slide 35
KEY PRACTICE POINTS
• Produce a prepared, proactive health care team to manage chronic conditions• Create effective clinical information systems e.g. disease registry, comprehensive
medical records• Translate CPG recommendations into daily clinical practice• Empower patients to self-manage their conditions• Perform continuous quality improvement activities e.g. Clinical Audit
02.Layout 10/18/10 12:50 PM Page 19
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
20
INTR
OD
UC
TIO
N&
OV
ER
VIE
WO
FH
PT
BU
RD
EN
INM
ALA
YS
IA
02.Layout 10/18/10 12:50 PM Page 20
02.Layout 10/18/10 12:50 PM Page 21
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
22
Slide 1
DISCUSSION POINT
• How do you confirm the diagnosis?• What would you do next?
• Mr. A• 38 years old• Male
• Divorced with 3 children• Delivery Man
VISIT 1
• Present to the clinic with acute URTI symptoms• BP 138/88 mmHg• Smoking 20 cig x 20 years• Beer 1-2/day• Sedentary lifestyle• Father hypertensive, hyperlipidaemic, AMI and CABG (age 68). • Wt 91kg, Ht 170cm, BMI 31.5, WC 97cm
Slide 2
Slide 3
HPT is a silent disease; 64% of cases remain undiagnosed. Therefore, BP should bemeasured at every chance encounter.
RECOMMENDATIONS FOR FOLLOW-UP BASED ON INITIAL BLOODPRESSURE MEASUREMENTS FOR ADULTS
Initial BP (mmHg)
Systolic Diastolic
Follow-up recommended to confirm diagnosis and/orreview response to treatment.
< 130 and < 85
130-139 and 85-89
140-159 and/or 90-99
160-179 and/or 100-109
180-209 and/or 110-119
Recheck in one year
Recheck within 3-6 months
Confirm within two months and treat if medium, high or veryhigh risks
Evaluate within one month and treat when confirmed
Look for symptoms and sign of hypertensive urgency oremergency, if asymptomatic, evaluate within one week andtreat whan confirmed
≥ 210 and/or ≥ 120 Initiate drug treatment immediately
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N1
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
PR
E-H
YP
ER
TEN
SIO
N
Case 1
02.Layout 10/18/10 12:50 PM Page 22
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
23
Slide 4
VISIT 1: FURTHER ACTIONS
• Explain to him that his BP is slightly high (best is < 120/80 mmHg). Explain thesignificance of the reading and the importance of confirming the diagnosis
• Assess cardiovascular risk factors:- Smoking- Obesity- Sedentary lifestyle- FH of hypertension and CVD
• Order further tests:- UFEME- Fasting lipids- Renal profile- ECG
• Arrange follow-up visit in 3 month
Slide 5
VISIT 2: BP REVIEW
• Mr. A came back to the clinic after 3 months• BP checked again in this visit – 138/88 mmHg (no change)• Renal profile and serum uric acid – normal• Fasting glucose normal• Fasting lipid profile normal• Urinalysis and UACR - normal• ECG – normal
Slide 6
DIAGNOSIS AND CLASSIFICATION OF HYPERTENSION
Mr. A’s average BP taken at the 2 visits = 138/88 mmHg
Optimal
Prehypertension
Stage 1 HPT
Stage 2 HPT
Stage 3 HPT
< 120
120-139
140-159
160-179
≥ 180
and
and/or
and/or
and/or
and/or
< 80
80-89
90-99
100-109
≥ 110
Diagnosis ofhypertension ismade based on theaverage of two ormore readings,taken at two ormore visits to thehealth careproviders
Category Systolic (mmHg) Diastolic (mmHg)
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N1
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
PR
E-H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 23
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
24
Slide 8
DISCUSSION POINT 2
• How do you manage Mr. A?
Slide 9
Slide 7
DEFINITION OF PREHYPERTENSION
Prehypertension is a defined as systolic BP (SBP) 120 to 139 or dictolic BP (SBP) 80 to 89mmHg, based on 2 or more properly measured seated BP readings on each of 2 or moreoffice visits.11
ALGORITHM FOR THE MANAGEMENT OF HYPERTENSION
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N1
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
PR
E-H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 24
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
25
Slide 10
Slide 11
Therapeutic lifestyle intervention should recommended for all patients with preHPT.
There is presently inadequate evidence for pharmacological intervention in preHPT patientsat low or moderate total CV risks.
CARDIOVASCULAR RISK STRATIFICATION
Co-existingCondition
BP Levels(mmHg)
SBP 120-139and/or
DBP 80-89Low Medium High Very High
SBP 140-159 and/or
DBP 90-99Low Medium High Very High
SBP 160-179 and/or
DBP 100-109Medium High Very High Very High
SBP 180-209 and/or
DBP 100-119High High Very High Very High
SBP ≥ 210 and/or
DBP ≥ 120Very High Very High Very High Very High
No RFNo TODNo TOC
TOD orRF (1-2),No TOC
TOD or RF (≥ 3) or Clinicalatherosclerosis
Previous MI orPrevious Stroke
or DiabetesMellitus (DM)
Slide 12
VISIT 2: SUMMARY OF MANAGEMENT PLAN FOR MR. A
• Educate regarding the diagnosis of Prehypertension and his CV risk stratification – medium risk
• Empower patient to self-manage through therapeutic lifestyle modification usingmotivational interviewing techniques - MR. A is motivated to stop smoking, reduce hisalcohol intake and reduce his weight
• Refer to the smoking cessation clinic• Provide information and leaflet on DASH eating plan• Review after 3 months and assess CV risks annually
Green Yellow Orange RedLegend:
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N1
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
PR
E-H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 25
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
26
Slide 13
DISCUSSION POINT 3
• How do you deliver therapeutic lifestyle modification advice?• How can you influence him to change his unhealthy lifestyle?
Slide 14
THERAPEUTIC LIFESTYLE MODIFICATION
Weightreduction
Aim for an ideal BMI (<23 kg/m2) or ideal wt (<66.5 kg). However aweight loss as little as 4.5 kg significantly reduces BP
Salt intake
An intake of < 100 mmol of sodium or 6g of sodium chloride aday is recommended (equivalent to < 1 1/4 teaspoonfuls of salt or3 teaspoonfuls of monosodium glutamate)
Alcohol intake
Standard advice is to restrict intake to no more than 21 units formen and 14 units for women per week (1 unit equivalent to 1/2 apint of beer or 100ml of wine or 20ml of proof whisky)
Physical activity
General advice on cardiovascular health would be for “milder”exercise, such as brisk walking 30 mins daily
DietA diet rich in fruits, vegetables and dairy products with reducedsaturated and total fat can substantially lower BP (11/6 mmHg inhypertensive patients and 4/2 mmHg in patients with high normal BP)
Smoking cessation
Cessation of smoking is important in the overall management ofthe patients with hypertension in reducing cardiovascular risk
Slide 15
MOTIVATIONAL INTERVIEWING
A collaborative person centred guidance strategy to elicit and strengthen motivation tochange. The goal is to increase intrinsic motivation, rather than to impose it externally. The‘spirit’ of Motivational Interviewing:• Collaborative: partnership between patients and health care providers• Evocative: evocating patient’s own motivation for change• Honouring autonomy: acceptance that patient make his/her own choice
Rollnick S, Miller WR, Butler CC. Motivational interviewing in health care: Helping patients change behaviour.New York: Guilford Press, 2008
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N1
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
PR
E-H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 26
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
27
Slide 16
MOTIVATIONAL INTERVIEWING USING CHANGE STRUCTURED CONSULTATION
CHECK : checking patient perspectivesHEAR : hearing what the patient saysAVOID : avoiding unsolicited adviceNOTE : noting the patient’s intentions and goalsGIVE : giving feedback to the patient when requestedEND : ending the interview with a summary of the patient’s plan
Slide 17
http:/www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf.
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N1
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
PR
E-H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 27
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
28
Slide 18
BEWARE OF HIDDEN SALTS
• Most salts/sodium are added duringfood processing, cooking and eating
• Very little are naturally occuring in diet
Slide 19http:/www.moh.gov.my/v/diet
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N1
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
PR
E-H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 28
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
29
Slide 20
Slide 21
SUMMARY OF EVIDENCE
• 37% of Malaysian population has Pre-HPT (NHMS II, 1996)• 2/3 of patients with pre-HPT progressed to stage 1 Hypertension over 4 year period
(TROPHY Study)• Pre-HPT tends to cluster with other CVD risk factors• Obesity and weight gain contributes to the progression• All pre-HPT should be managed with therapeutic lifestyle modification• Decisions regarding pharmacological treatment should be based on individual’s global
CVD risk
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N1
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
PR
E-H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 29
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
30
Slide 22
KEY LEARNING POINTS
• HPT is a silent disease; 64% of cases remain undiagnosed. Therefore, BP should bemeasured at every chance encounter
• PreHPT is defined as SBP 120-139 and/or DBP 80-89 mmHg, based on ≥ 2 BP readingsat ≥ 2 clinic visits
• Therapeutics lifestyle changes should be recommended for all individuals with HPT andpre-HPT
• Decision to commence pharmacological treatment should be based on globalcardiovascular risks and not on the level of blood pressure (BP) per se
• There is presently inadequate evidence for pharmacological intervention in preHPTpatients at low or moderate total CV risks
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N1
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
PR
E-H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 30
02.Layout 10/18/10 12:50 PM Page 31
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
32
Slide 1
• Mr. MN• 40 years old• Male
• Married with 3children
• Clerk
VISIT 1
• Came to the clinic c/o of sore throat• Otherwise well – no other symptom• Smoker – 20 cigarettes a day• Temperature 36.5° C, BP 150/90 mmHg
• Throat and chest examinations – unremarkable
• Diagnosis of viral URTI was made and symptomatic treatment was given
Slide 2
DISCUSSION POINT 1
• What would you do now?• How do you explain your plan to the patient?
Slide 3
HPT is a silent disease; 64% of cases remain undiagnosed. Therefore, BP should bemeasured at every chance encounter.
RECOMMENDATIONS OF FOLLOW-UP BASED ON INITIAL BLOODPRESSURE MEASUREMENTS FOR ADULTS
Initial BP (mmHg)
Systolic Diastolic
Follow-up recommended to confirm diagnosis and/orreview response to treatment.
< 130 and < 85
130-139 and 85-89
140-159 and/or 90-99
160-179 and/or 100-109
180-209 and/or 110-119
Recheck in one year
Recheck within 3-6 months
Confirm within two months and treat if medium, high or veryhigh risks
Evaluate within one month and treat when confirmed
Look for symptoms and sign of hypertensive urgency oremergency, if asymptomatic, evaluate within one week andtreat whan confirmed
≥ 210 and/or ≥ 120 Initiate drug treatment immediately
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
Case 2
02.Layout 10/18/10 12:50 PM Page 32
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
33
Slide 4
VISIT 1: FURTHER ACTIONS
• Explain to him that he has a raised BP (150/90 mmHg)• Explain the significance of the reading and the importance of confirming the diagnosis• Advise to stop smoking• Negotiate the management plan:
1. Arrange to see the nurse/AMO for BP check within 1 month 2. Arrange baseline investigations3. Arrange follow-up visit within 2 months
Slide 5
VISIT 2: BP REVIEW
• Mr. MN came back to the clinic after 2 months• Feeling very well generally• BP checked by nurse a month ago – 148/90 mmHg• BP checked again in this visit – 150/92 mmHg
Slide 6
DISCUSSION POINT 2
• What is the diagnosis?• What is your next step of action?
Slide 7
DIAGNOSIS AND CLASSIFICATION OF HYPERTENSION
Mr. MN’s average BP taken at the 3 visits = 149/90 mmHg
Optimal
Prehypertension
Stage 1 HPT
Stage 2 HPT
Stage 3 HPT
< 120
120-139
140-159
160-179
≥ 180
and
and/or
and/or
and/or
and/or
< 80
80-89
90-99
100-109
≥ 110
Diagnosis ofhypertension ismade based on theaverage of two ormore readings,taken at two ormore visits to thehealth careproviders
Category Systolic (mmHg) Diastolic (mmHg)
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 33
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
34
Slide 8
EVALUATION
EVALUATION OF NEWLY DIAGNOSED HYPERTENSIVE PATIENTSEvaluation should include through history, physical examination and relevantinvestigations.
Three main objectives:1. To exclude secondary causes of hypertension.2. To ascertain the presence of target organ damage (TOD).3. To assess lifestyle and identity other cardiovascular risk factors and/or concomitant
disoders that may affect treatment and prognosis.
Slide 9
VISIT 2: FURTHER HISTORY
• Still smoking 20 cigarettes a day and not ready to stop• Eat out regularly with family and friends• No time to do any exercise• No significant past medical history • Not on any regular medication• Mother (aged 70) has hypertension• No family history of heart attacks or strokes• No symptoms to suggest target organ damage, e.g. chest pain, blurred vision• No symptoms to suggest secondary causes of hypertension
Slide 10
VISIT 2: PHYSICAL EXAMINATION FINDINGS
• BMI 26 kg/m2
• Waist circumference (WC) 88 cm• Fundoscopy normal• Cardiovascular examinations – normal • Chest examinations – normal• Abdominal examinations – normal• Neurological examinations – normal
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 34
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
35
Slide 11
BASELINE INVESTIGATIONS
• Full blood count• Urinalysis• Urine albumin excretion or albumin/creatinine ratio• Renal profile and serum uric acid• Fasting blood sugar• Fasting lipid profile• Electrocardiogram (ECG)• Chest X-ray (if clinically indicated)
Note : Should be repeated 6-12 monthly thereafter (except for Chest X-Ray)
Slide 12
VISIT 2: BASELINE INVESTIGATION RESULTS
• Renal Profile and serum uric acid - normal• Full Blood Count - normal • Fasting Blood Sugar 5.4 mmol/l• Fasting Lipid Profile:
- Total cholesterol 6.7 mmol/l- Triglycerides 2.0 mmol/l- HDL 0.9 mmol/l- LDL 3.4 mmol/l
• Urinalysis and UACR - normal• ECG - normal
Slide 13
DISCUSSION POINT 3
• How do you manage Mr. MN?• What is your next step of action
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 35
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
36
Slide 14
ALGORITHM FOR THE MANAGEMENT OF HYPERTENSION
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 36
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
37
Slide 15
CARDIOVASCULAR RISK STRATIFICATION
Co-existingCondition
BP Levels(mmHg)
SBP 120-139and/or
DBP 80-89Low Medium High Very High
SBP 140-159 and/or
DBP 90-99Low Medium High Very High
SBP 160-179 and/or
DBP 100-109Medium High Very High Very High
SBP 180-209 and/or
DBP 100-119High High Very High Very High
SBP ≥ 210 and/or
DBP ≥ 120Very High Very High Very High Very High
No RFNo TODNo TOC
TOD orRF (1-2),No TOC
TOD or RF (≥ 3) or Clinicalatherosclerosis
Previous MI orPrevious Stroke
or DiabetesMellitus (DM)
Risk Level Risk of major CV event in 10 years Management
Low < 10% Lifestyle changes
Medium 10-20% Drug treatment and lifestylechanges
High 20-30% Drug treatment and lifestylechanges
Very High > 30% Drug treatment and lifestylechanges
TOD : LVH, Retinopathy, Proteinuria / TOC : Heart Failure, Renal Failure)Risk Factors (RF): additional RF (smoking, TC > 6.5 mmol/L, family history of premature vascular disease) Clinicalatherosclerosis (CHD, carotid stenosis, peripheral vascular disease, TIA, stroke)MI: Mycardial Infarction
Slide 16
DISCUSSION POINT 4
• How do you deliver therapeutic lifestyle modification advice?• How do you commence pharmacotherapy?• Which antihypertensive agent would you choose as first line?• What is the target blood pressure?• When would you see him again?
Green Yellow Orange RedLegend:
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 37
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
38
Slide 17
THERAPEUTIC LIFESTYLE MODIFICATION
Therapeutic lifestyle modification is the first line treatment in all patients with Hypertension
Weightreduction
Aim for an ideal BMI (<23 kg/m2) or ideal wt (<66.5 kg). However aweight loss as little as 4.5 kg significantly reduces BP
Salt intake
An intake of < 100 mmol of sodium or 6g of sodium chloride aday is recommended (equivalent to < 1 1/4 teaspoonfuls of salt or3 teaspoonfuls of monosodium glutamate)
Alcohol intake
Standard advice is to restrict intake to no more than 21 units formen and 14 units for women per week (1 unit equivalent to 1/2 apint of beer or 100ml of wine or 20ml of proof whisky)
Physical activity
General advice on cardiovascular health would be for “milder”exercise, such as brisk walking 30 mins daily
DietA diet rich in fruits, vegetables and dairy products with reducedsaturated and total fat can substantially lower BP (11/6 mmHg inhypertensive patients and 4/2 mmHg in patients with high normal BP)
Smoking cessation
Cessation of smoking is important in the overall management ofthe patients with hypertension in reducing cardiovascular risk
Slide 18
PHARMACOLOGICAL MANAGEMENT OF STAGE 1 HYPERTENSION
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 38
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
39
Slide 19
CHOICE OF FIRST LINE MONOTHERAPY
• In patients with newly diagnosed uncomplicated hypertension who have nocompelling indications, choice of first line monotherapy includes ACEIs, ARBs, CCBsand Diuretics
• β-blockers are no longer recommended for first line monotherapy in this group ofpatients
• However, it may be considered in younger people, particularly those who are intolerantor contraindicated to ACEI or ARB, women of child bearing potential and patientswith evidence of increased sympathetic drive
Slide 20
BLOOD PRESSURE TREATMENT TARGETS
Category Target blood pressure (mmHg)
Uncomplicated hypertension < 140/90
Hypertension in high risk groups: DM, History of CVD < 130/80
Diabetics with proteinuria of > 1 g/24 hours < 125/75
Once target BP is achieved, follow-up at 3-6 month interval is appropriate.
Slide 21
VISIT 2: SUMMARY OF MANAGEMENT PLAN FOR MR. MN
• Educate regarding the diagnosis of Stage 1 Hypertension, its associated CV risk factors and potential complications
• Educate regarding BP treatment target < 140/90 mmHg, choice of medication – potential benefits vs side effects
• Empower patient to self-manage through therapeutic lifestyle modification.• Commence a single antihypertensive agent at low dose e.g. ACE Inhibitor• Commence statin therapy for mixed dyslipidaemia• Arrange Renal Profile to be done within 2 weeks (post ACEi)• Review after 1 month
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 39
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
40
Slide 22
VISIT 3: FOLLOW UP
• Mr. MN came for review after 1 month• His Renal Profile was normal• Feeling very well generally• No side effect of ACE Inhibitor or statin• Still smoking• Dietary habit – no change• Started to do some gardening and walk around his neighborhood BP checked again in
this visit – 146/86 mmHg• BMI and WC – no change
Slide 23
DISCUSSION POINT 5
• What is the state of his BP control?• How would you manage Mr. MN at this stage?• What is your next step of action?
Slide 24
PHARMACOLOGICAL MANAGEMENT OF STAGE 1 HYPERTENSION
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 40
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
41
Slide 25
VISIT 3: SUMMARY OF MANAGEMENT PLAN FOR MR. MN
• Educate regarding the state of his BP control - treatment target < 140/90 mmHg is still not achieved
• Re-emphasize therapeutic lifestyle modification:- Smoking cessation, healthy eating, exercise
• Increase the dose of ACE Inhibitor• Recheck Renal Profile within 2 weeks • Review after 1 month
- If well-controlled – continue treatment, review 3-6 monthly- If uncontrolled – see algorithm for management of Stage 1 HPT
• Continue long-term follow up• Assess CV risks annually
Slide 26
SUMMARY OF EVIDENCE
• Monotherapy can lower BP to < 140/90 mmHg in 40%- 60% of patients with mild tomoderate HPT
• β-blockers – no longer recommended for 1 line monotherapy in newly diagnoseduncomplicated HPT
• Meta-analysis has shown that ß-blockers is not as effective in lowering BP and inprevention of stroke compared to other agents
• Incidence of new-onset diabetes with β-blockers is also higher compared to other drugs
Slide 27
KEY LEARNING POINTS
• HPT is a silent disease; 64% of cases remain undiagnosed. Therefore, BP should be measured at every chance encounter
• Stage 1 HPT is defined as SBP 140-159 and/or DBP 90-99 mmHg, based on ≥ 2 BP readings at ≥ 2 clinic visits
• Therapeutic lifestyle changes should be recommended for all individuals with HPT and pre-HPT
• Decision to commence pharmacologica treatment should be based on global cardiovascular risks and not on the level of blood pressure (BP) per se
• In patients with newly diagnosed uncomplicated HPT who have no compelling indicatons, choice of first line monotherapy includes ACEIs’ ARBs, CCBs and Diuretics. ß-blockers are no longer recommended as first line monotherapy
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 41
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
42
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N2
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
1H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 42
02.Layout 10/18/10 12:50 PM Page 43
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
44
Slide 1
• Mr. NKH• 45 years old• Male
• Teacher• Non-smoker
VISIT 1
• Came to the clinic with referral letter • Found to have high BP in a health screening
campaign (160/100 mmHg) • Remained well & asymptomatic• BP checked again in this visit – 164/100 mmHg
Slide 2
DISCUSSION POINT 1
• What is your diagnosis?• How would you evaluate his problem?
Slide 3
DIAGNOSIS
CLASSIFICATION OF BLOOD PRESSURE (adults ≥ 18 years)
Optimal
Prehypertension
Stage 1 HPT
Stage 2 HPT
Stage 3 HPT
< 120
120-139
140-159
160-179
≥ 180
and
and/or
and/or
and/or
and/or
< 80
80-89
90-99
100-109
≥ 110
Diagnosis ofhypertension ismade based on theaverage of two ormore readings,taken at two ormore visits to thehealth careproviders
Category Systolic (mmHg) Diastolic (mmHg)
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N3
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
2H
YP
ER
TEN
SIO
N&
RE
SIS
TAN
TH
YP
ER
TEN
SIO
N
Case 3
02.Layout 10/18/10 12:50 PM Page 44
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
45
Slide 4
EVALUATION
EVALUATION OF NEWLY DIAGNOSED HYPERTENSIVE PATIENTSEvaluation should include through history, physical examination and relevantinvestigations.
Three main objectives:1. To exclude secondary causes of hypertension.2. To ascertain the presence of target organ damage (TOD).3. To assess lifestyle and identity other cardiovascular risk factors and/or concomitant
disoders that may affect treatment and prognosis.
Slide 5
VISIT 1: FURTHER INFORMATION
• Exercised 3x/week • Not known to have any medical problem• No family history of premature CVD• BMI= 22.8 kg/m2
• Other physical examinations: unremarkable• Normal ECG & urine analysis• Normal diabetic & dyslipidaemia screening
Slide 6
DISCUSSION POINT 2
• How would you risk-stratify him?• Can you estimate his 10-year CV risk?• How would you manage this patient?
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N3
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
2H
YP
ER
TEN
SIO
N&
RE
SIS
TAN
TH
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 45
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
46
Slide 8
10 YEAR CV RISK ESTIMATION
Slide 7
CARDIOVASCULAR RISK STRATIFICATION
Co-existingCondition
BP Levels(mmHg)
SBP 120-139and/or
DBP 80-89Low Medium High Very High
SBP 140-159 and/or
DBP 90-99Low Medium High Very High
SBP 160-179 and/or
DBP 100-109Medium High Very High Very High
SBP 180-209 and/or
DBP 100-119High High Very High Very High
SBP ≥ 210 and/or
DBP ≥ 120Very High Very High Very High Very High
No RFNo TODNo TOC
TOD orRF (1-2),No TOC
TOD or RF (≥ 3) or Clinicalatherosclerosis
Previous MI orPrevious Stroke
or DiabetesMellitus (DM)
Risk Level Risk of major CV event in 10 years
Low < 10%
Medium 10-20%
High 20-30%
Very High > 30%
Green Yellow Orange RedLegend:
Green Yellow Orange RedLegend:
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N3
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
2H
YP
ER
TEN
SIO
N&
RE
SIS
TAN
TH
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 46
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
47
Slide 9
ALGORITHM FOR THE MANAGEMENT OF HYPERTENSION
Slide 10
DISCUSSION POINT 3
• How do you commence pharmacotherapy?• What drugs would you consider?• What is his BP treatment target?• When would you see him again?
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N3
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
2H
YP
ER
TEN
SIO
N&
RE
SIS
TAN
TH
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 47
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
48
Slide 11
CHOICE OF PHARMACOTHERAPY
Pharmalogical management of stage 2 hypertensionInitiating therapy with the right combination of at least 2 drugs is recommended
Effective Combination
β-blockers + diuretics
β-blockers + CCBs
CCBs + ACEIs/ARBs
ACEIs + diuretics
ARBs + diuretics
Slide 12
CHOICE OF ANTIHYPERTENSIVE AGENTS IN PATIENTS WITHCONCOMITANT CONDITIONS
Diabetes mellitus (without nephropathy) + +/- +++ + +/- ++
Diabetes mellitus (with nephropathy) ++ +/- +++ ++* +/- +++
Gout +/- + + + + +
Dyslipidaemia +/- +/- + + + +
Coronary heart disease + +++ +++ ++ + ++
Heart failure +++ +++# +++ +@ + +++
Asthma + - + + + +
Peripheral vascular disease + +/- + + + +
Non-diabetic renal impairment ++ + +++ +* + ++
Renal artery stenosis + + ++$ + + ++$
Elderly with no co-morbid conditions +++ + + +++ +/- +
Very elderly (> 80 years old) with no +++ + ++ + +/- +co-morbid conditions
Concomitant disease Diuretics β-blockers ACEIs CCBs Peripheral α-blockers ARBs
The grading of recommendation from (+) to (+++) is based on increasing levels of evidence and/or current widely accepted practice+/- Use with care- Contraindicated* Only non-dihydropyridine CCB# Metoprolol, bisoprolol, carvedilol – dose needs to be gradually titrated@ Current evidence available for amlodipine and felodipine only$ Contraindicated in bilateral renal artery stenosis
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N3
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
2H
YP
ER
TEN
SIO
N&
RE
SIS
TAN
TH
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 48
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
49
Slide 14
VISIT 1: SUMMARY OF MANAGEMENT PLAN FOR MR. NKH
• Explain to him that he has Stage 2 HPT and he has medium CV risk• Deliver therapeutic lifestyle modification advice• Educate regarding potential complications, the need to start medication and his
treatment target• Initiate therapy with 2 drugs e.g. CCB + ACEi• Review monthly until target BP is achieved• Review 3-monthly once target BP is achieved• Re-assess CV risks annually
Slide 15
VISIT 2
• Mr. NKH continued his follow-up at a GP• Treated with 3 anti-HPTs (Felodipine 10 mg od + FORTZAAR® 100-50) for 6 months• Reason for re-visit: request to continue treatment• BP remained uncontrolled (150/90 mmHg)• Asymptomatic• Normal physical examination
Slide 13
BLOOD PRESSURE TREATMENT TARGETS
Category Target blood pressure (mmHg)
Uncomplicated HPT < 140/90
Hypertension in high risk groups < 130/80
Diabetics with proteinuria of (> 1 g/24 hours) < 125/75
Once target BP is achieved, follow-up at 3-6 month interval is appropriate.
Slide 16
DISCUSSION POINT 4
• What is your diagnosis?• What are the possible causes would you consider?• How would you evaluate this patient?
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N3
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
2H
YP
ER
TEN
SIO
N&
RE
SIS
TAN
TH
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 49
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
50
Slide 17
RESISTANT HYPERTENSION
BP remains > 140/90 mmHg *with 3 anti-HPTs (including if possible a diuretic)
* > 130/80 mmHg in patients with diabetes or chronic kidney disease
• Possible causes:- Non-compliance
Pseudoresistance- White coat HPT- Poor diet control*- Complications of long standing HPT- Secondary HPT
*excessive sodium intake, excessive liquorice intake and drug interactions
Slide 18
EVALUATION OF RESISTANT HYPERTENSION
• Exclude pseudoresistant:- Is patient adherent with prescribed regimen?- Obtain home/ ambulatory BP to exclude white coat effect
• Identify contributing lifestyle factors & drug interaction:- Obesity, physical inactivity, excessive alcohol/ salt intake, low-fiber diet, NSAIDs &
stimulants etc• Look for secondary causes of HPT • Exclude complications of long-standing HPT
Slide 19
VISIT 2: FURTHER INFORMATION
• Mr. NKH is compliant with the treatment regime• No sleeping problem identified• No White Coat effect detected• Like to enjoy taking high salt diet• Normal renal profile• Normal U/S ABD & KUB• No secondary causes/complications of HPT detected
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N3
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
2H
YP
ER
TEN
SIO
N&
RE
SIS
TAN
TH
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 50
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
51
Slide 20
DISCUSSION POINT 5
• How would you manage this patient?• How would you maximize his concordance to the treatment plan?• When would you consider to refer this patient?
Slide 21
VISIT 2: SUMMARY OF MANAGEMENT PLAN FOR MR. NKH
• Explain to him that he has resistant hypertension• Strengthen therapeutic lifestyle modification advice• Reverse contributing factors (reduce salt intake)• Re-educate regarding his potential complications & treatment target• Continue & optimize his current treatment regime (CCB + ARB + Diuretic)• Review monthly until target BP is achieved• Review 3-monthly once target BP is achieved• Re-assess CV risks annually
Slide 22
WAYS TO ACHIEVE TREATMENT CONCORDANCE
• Develop rapport with patients• Regard patients as partners in managing their conditions• Educate patient regarding their conditions• Influence behaviour change through motivational interviewing skills• Check on drug adverse effects regularly• Adhere to CPG recommendations
Slide 23
RESISTANT HPT : WHEN TO REFER?
• Refer to specialist for known or suspected secondary cause(s) of hypertension• Refer to specialist if BP remains uncontrolled after 6 months of treatment• Refer if you are not sure
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N3
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
2H
YP
ER
TEN
SIO
N&
RE
SIS
TAN
TH
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 51
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
52
Slide 24
KEY LEARNING POINTS
• Stage 2 HPT is defined as SBP 160-179 and/or DBP 100-109 mmHg, based on ≥ 2 BP readings at ≥ 2 clinic visits
• Therapeutics lifestyle changes should be recommended for all individuals with HPT and pre-HPT
• Combination of at least 2 drugs is recommended once diagnosis is confirmed• Once BP is controlled, most patients will require lifelong treatment• If BP is still > 140/90 mmHg with 3 drugs (including diuretics at optimal doses), patients
by definition have resistant HPT
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N3
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
2H
YP
ER
TEN
SIO
N&
RE
SIS
TAN
TH
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 52
53
02.Layout 10/18/10 12:50 PM Page 53
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
54
Slide 1
• Mdm. ZBL• 48 years old• Smoker
• Married with 5 children
• Housewife
VISIT 1• Came to the clinic c/o mild, intermittent throbbing
headaches• No alarm symptom• Diagnosed to have HPT 10 years ago• Defaulted on her follow up since the last 5 years
as she felt well
• BMI 25 kg/m2, Waist Circumference (WC) 80cm
• BP 194/110 mmHg
Slide 2
DISCUSSION POINT 1
• What further history would you elicit from this patient?• Comment on the physical examination findings?• Give other relevant physical examinations needed to be performed?• What investigations would you arrange for this patient?
Slide 3
VISIT 1: FURTHER HISTORY
• Smokes 10 cigs a day for the past 20 years• Loves to cook and family loves her food • No time to do any exercise - busy with family routines• Has been buying her antihypertensive ‘tablets’ from the pharmacy on and off
• Currently not on any medication
• Mother (aged 75) has hypertension
• No family history of heart attack or stroke• No symptoms to suggest target organ damage (e.g. chest pain, blurred vision)• No symptoms to suggest secondary causes of HPT
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N4
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
3H
YP
ER
TEN
SIO
N
Case 4
02.Layout 10/18/10 12:50 PM Page 54
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
55
Slide 4
VISIT 1: FURTHER EXAMINATION FINDINGS
• Cardiovascular examination – S1 S2 heard, Grade 2 systolic murmur best heard at left sternal edge
• Respiratory examination-normal• Other systems revealed no significant abnormality
Slide 5
FUNDOSCOPY
Grade III hypertensiveretinopathy - note the flamehemorrhage (rupturedmicroaneurysm) directly superiorto the optic disc (pale area at 5o'clock). The white lesions(arrow) are well demarcated andrepresent hard exudates(increased vessel permeability).There is no papilledema.
Slide 6
VISIT 1: FURTHER EXAMINATION FINDINGS
• BP checked again after 30 minutes bed rest: 190/108 mmHg
Slide 7
URGENT INVESTIGATIONS
• Electrocardiogram (ECG)• Urinalysis (UFEME)• Random blood glucose
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N4
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
3H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 55
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
56
Slide 8
VISIT 1: INVESTIGATION RESULTS
• Urinalysis – proteinuria 2+
Slide 9
ECG RESULTS
Slide 10
DISCUSSION POINT 2
• What is the diagnosis?• How many target organ damages/ complications has she got?• Could you estimate her global CV risk?• How would you manage this patient?
ECG showed thepresence of LVH – tall Rwave in V6 with T waveinversions in V4-V6(strain patterns)
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N4
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
3H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 56
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
57
Slide 11
SEVERE HYPERTENSION
Severe hypertension is defined as BP > 180/110 mmHg(persistent elevation after 30 minutes bed rest)
Asymptomatic severeHPT• Incidental findings• Non-specific
symptoms likeheadache, dizziness,lethargy
Management• Most can be managed
as outpatient• Review existing drug
regime andcompliance
• For newly-diagnosed,consider admissionfor evaluation
• For established HPT,admit if complianceremains a problem
Hypertensiveurgencies• Presents with grade III
or IV retinal changes,or proteinuria ≥ 2+, butno overt organ failure
Management• Initial treatment
should aim for 25%reduction in BP over24 hours but notlower than 160/90mmHg
• Combination therapyis often necessary(see table below)
• Admit patient if BPremain > 180/110mmHg
Hypertensiveemergencies• Presents with
symptoms and signsof TOC e.g. acuteheart failure,subarachnoidhaemorrhage, acutecoronary syndromes
Management • All patient should be
admitted• Aim to reduce BP by
25% over 3-12 hoursbut not lower than160/90 mmHg
• Best achieved withparenteral drugs
Possible clinical scenarios
Slide 12
MANIFESTATIONS OF TOD/TARGET ORGAN COMPLICATION (TOC)
Cardiac
Cerebrovascular
Peripheralvasculature
Renal
Retinopathy
Organ System Manifestations
Left ventricular hypertrophy (LVH), coronary heart disease (CHD),heart failure.
Transient ischaemic attack (TIA), stroke.
Absence of one or more major pulses in extremities (exceptdorsalis pedis) with or without intermittent claudication.
GFR < 60ml/min/1.73m2, proteinuria (≥1+), microalbuminuria (2 outof 3 positive tests over a period of 4-6 months).
Haemorrhages or exudates, with or without papilloedema.
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N4
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
3H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 57
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
58
Slide 14
TREATMENT OPTIONS FOR HYPERTENSIVE URGENSIES (ORAL)
Slide 15
Rapid reduction of BP (within minutes to hours) in asymptomatic severe HPT or hypertensiveurgencies is best avoided as it may precipitate ischaemic events.
Slide 13
CARDIOVASCULAR RISK STRATIFICATION
Co-existingCondition
BP Levels(mmHg)
SBP 120-139and/or
DBP 80-89Low Medium High Very High
SBP 140-159 and/or
DBP 90-99Low Medium High Very High
SBP 160-179 and/or
DBP 100-109Medium High Very High Very High
SBP 180-209 and/or
DBP 100-119High High Very High Very High
SBP ≥ 210 and/or
DBP ≥ 120Very High Very High Very High Very High
No RFNo TODNo TOC
TOD orRF (1-2),No TOC
TOD or RF (≥ 3) or Clinicalatherosclerosis
Previous MI orPrevious Stroke
or DiabetesMellitus (DM)
Drug
Captopril
Nifedipine
Labetalol
Dose
25 mg
10-20 mg
200-400 mg
Onset of action (hr)
0.5
0.5
2.0
Duration (hr)
6
3-5
6
Frequency (hr)
1-2 hrs
1-2 hrs
4 hrs
Green Yellow Orange RedLegend:
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N4
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
3H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 58
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
59
Slide 16
VISIT 1: SUMMARY OF MANAGEMENT PLAN FOR MRS. ZBL
• Explain to her that she has Stage 3 HPT (Hypertensive Urgencies) with very high CV risk
• Explain the significance of the diagnosis and the importance to stabilize her blood pressure
• Give nifedipine 10mg tablet orally as a stat dose (BP measured again after 30 minutes bed rest : 186/100 mmHg)
• Explain to her that she needs to be admitted to the nearest hospital as her BP remains high
Slide 17
VISIT 2: BP REVIEW
• Mdm. ZBL came back to the clinic 1 week after being discharged from the hospital.• Feeling well generally• She brought along a discharge summary from the hospital which contains the
following informations:Medications: - Amlodipine 10 mg daily
- Perindopril 8 mg daily- Simvastatin 40 mg nocte
Investigations: - FBS 5.8 mmol/l, Renal Profile normal.- TC 6.7, TG 2.6, HDL 1.3, LDL 3.4 (all in mmol/litres).- Liver Function Test normal- Urine Microalbumin positive- Awaiting ECHO appointment
• BP examination done in the clinic – 156/90 mmHg
Slide 18
DISCUSSION POINT 3
• Summarise her current problems.• How would you manage this lady now?• What is her target blood pressure?
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N4
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
3H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 59
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
60
Slide 19
THERAPEUTIC LIFESTYLE MODIFICATION
Therapeutic lifestyle modification is the first line treatment in all patients with Hypertension
Weightreduction
Aim for an ideal BMI (<23 kg/m2) or ideal wt (<66.5 kg). However aweight loss as little as 4.5 kg significantly reduces BP
Salt intake
An intake of < 100 mmol of sodium or 6g of sodium chloride aday is recommended (equivalent to < 1 1/4 teaspoonfuls of salt or3 teaspoonfuls of monosodium glutamate)
Alcohol intake
Standard advice is to restrict intake to no more than 21 units formen and 14 units for women per week (1 unit equivalent to 1/2 apint of beer or 100ml of wine or 20ml of proof whisky)
Physical activity
General advice on cardiovascular health would be for “milder”exercise, such as brisk walking 30 mins daily
DietA diet rich in fruits, vegetables and dairy products with reducedsaturated and total fat can substantially lower BP (11/6 mmHg inhypertensive patients and 4/2 mmHg in patients with high normal BP)
Smoking cessation
Cessation of smoking is important in the overall management ofthe patients with hypertension in reducing cardiovascular risk
Slide 20
BLOOD PRESSURE TREATMENT TARGETS
Category Target blood pressure (mmHg)
Uncomplicated HPT < 140/90
Hypertension in high risk groups < 130/80
Diabetics with proteinuria of (> 1 g/24 hours) < 125/75
Once target BP is achieved, follow-up at 3-6 month interval is appropriate.
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N4
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
3H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 60
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
61
Slide 21
SUMMARY OF MDM. ZBL’S PROBLEMS:
1. Uncontrolled hypertension (Target BP < 130/80)2. Very high CV risk with multiple TODs (LVH, proteinuria and Grade III Hypertensive Retinopathy 3. Overweight4. Sedentary lifestyle5. Smoker6. Unhealthy dietary habit
Slide 22
VISIT 2: SUMMARY OF MANAGEMENT PLAN FOR MDM. ZBL
• Educate regarding the state of her BP control - treatment target < 130/80 mmHg• Re-emphasize therapeutic lifestyle modification• Influence behaviour change through motivational interviewing techniques• Add another type of antihypertensive agent e.g. thiazide diuretics• Review monthly until target BP is achieved• Review 3-monthly once target BP is achieved• Consider resistant HPT if BP remains uncontrolled with 3 agents (including diuretics at
maximum dose)• Assess CV risks annually
Slide 23
DISCUSSION POINT 4
• What is the commonest cause of severe HPT?• How would you maximize her concordance to the treatment plan?
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N4
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
3H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 61
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
62
Slide 24
COMMON CAUSES OF SEVERE HYPERTENSIONThe most common cause of severe hypertension is still long standing poorly controlledessential hypertension
Slide 25
WAYS TO ACHIEVE TREATMENT CONCORDANCE
• Develop rapport with patients• Regard patients as partners in managing
their conditions• Educate patient regarding their conditions
• Influence behaviour change throughmotivational interviewing techniques
• Check on drug adverse effects regularly• Adhere to CPG recommendations
Slide 26
KEY LEARNING POINTS
• Stage 3 HPT is defined as SBP > 180 and/or DBP 110 mmHg, based on > 2 BP readings at > 2 clinic visits
• Rapid reduction of BP (within minutes to hours) in asymptomatic severe hypertension or hypertensive urgencies is best avoided as it may precipitate ischaemic events
• Emphasis on the therapeutic lifestyle intervention must be done at every clinic visit• Combination therapy is recommended in patients presenting with stage 2 hypertension or
beyond• If BP is still > 140/90 mmHg with 3 drugs (including diuretics at maximum doses),
patients by definition have resistant HPT
Renal parenchymal disease
Systematic disorders withrenal involvement
Renovascular
Endocrine
Drug
Coarctation of Aorta
Pre-eclampsia/eclampsia
• Chronic pyelonephritis • Primary glomerulonephritis• Tubulointerstitial nephritis
• Systemic lupus • Systemic sclerosis erythematosus • Vasculitides
• Atherosclerotic disease • Polyarteritis nodosa• Fibromuscular dysplasia
• Pheochromocytoma • Conn Syndrome (primary • Cushing syndrome hyperaldosteronism)
• Cocaine • Cyclosporin • Amphetamines • Clodine withdrawal
-
-
Cause Example
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N4
DIA
GN
OS
ISA
ND
MA
NA
GE
ME
NT
OF
STA
GE
3H
YP
ER
TEN
SIO
N
02.Layout 10/18/10 12:50 PM Page 62
63
02.Layout 10/18/10 12:50 PM Page 63
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
64
Slide 1
• Mr. LM• 51-year-old
• Married with 4 girls• Lorry driver for a
paint factory
VISIT 1
• Referred by a GP to the health clinic for insulin initiation
• c/o tiredness & blurring of vision for 2 weeks• Diabetes since 2005, on Metformin 1 g BD, Gliclazide
80mg BD & Simvastatin 40 mg ON• Poor adherence to low sugar diet & exercise• Non-smoker & non-alcoholic
Slide 2
VISIT 1: PHYSICAL EXAMINATIONS
• Blood pressure 140/90 mmHg (average of 2 readings)• Weight 74 kg & Height 170 cm, BMI 25.6kg/m2
• Bilateral cataracts • Peripheral neuropathy of both lower limbs
Slide 3
VISIT 1: INVESTIGATION RESULTS FROM THE GP
• HbA1c 11.5%• FBS 10.8 mmol/L
• LDL-C 3.6 mmol/L
• TG 1.75 mmol/L• Urine albumin 2+, repeat in the clinic 1+• Renal function normal
• Liver function normal
• ECG stat in the clinic normal
Slide 4
DISCUSSION POINT 1
• What are his problems?• How would you tell him?
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N5
HY
PE
RTE
NS
ION
AN
DD
IAB
ETE
S
Case 5
02.Layout 10/18/10 12:50 PM Page 64
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
65
Slide 5
SUMMARY OF MR. LM’S CLINICAL PROBLEMS
• Uncontrolled diabetes with- Nephropathy- Cataract? retinopathy- Peripheral neuropathy
• Unhealthy diet and low physical activity• Dyslipidemia• Hypertension
Slide 6
HOW COMMON IS HYPERTENSION IN PATIENTS WITH DIABETES MELLITUS?
• The Hypertension in Diabetes Study Group reported a 39% prevalence of hypertension among newly diagnosed diabetic patients
• In half of the diabetes patients, the elevated BP presents before the onset of microalbuminuria
• Strongly associated with obesity • Hypertension is frequently present as a component of the metabolic syndrome
Slide 7
DIAGNOSIS
Hypertension should be detected and treated early in the course of diabetes mellitus to • prevent cardiovascular disease and • delay the progression of renal disease and • delay diabetic retinopathy
Slide 8
VISIT 1: FURTHER HISTORY
• Eat at the factory cafeteria 4 times per day (breakfast, morning snack, lunch & afternoon snack) with teh tarik 3 times per day
• Unable to drive company lorry due to vision problem (loss of income)• No time to do exercise• Compliant to his medication • No home sugar or BP monitoring• Wife has recently been diagnosed to have breast cancer• Mother had hypertension & diabetes, died of stroke (aged 60)
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N5
HY
PE
RTE
NS
ION
AN
DD
IAB
ETE
S
02.Layout 10/18/10 12:50 PM Page 65
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
66
Slide 9
DISCUSSION POINT 2
• How do you manage Mr. LM?• What is your next step of action?
Slide 10
CARDIOVASCULAR RISK STRATIFICATION
Co-existingCondition
BP Levels(mmHg)
SBP 120-139and/or
DBP 80-89Low Medium High Very High
SBP 140-159 and/or
DBP 90-99Low Medium High Very High
SBP 160-179 and/or
DBP 100-109Medium High Very High Very High
SBP 180-209 and/or
DBP 100-119High High Very High Very High
SBP ≥ 210 and/or
DBP ≥ 120Very High Very High Very High Very High
No RFNo TODNo TOC
TOD orRF (1-2),No TOC
TOD or RF (≥ 3) or Clinicalatherosclerosis
Previous MI orPrevious Stroke
or DiabetesMellitus (DM)
Risk Level Risk of major CV event in 10 years Management
Low < 10% Lifestyle changes
Medium 10-20% Drug treatment and lifestylechanges
High 20-30% Drug treatment and lifestylechanges
Very High > 30% Drug treatment and lifestylechanges
TOD : LVH, Retinopathy, Proteinuria / TOC : Heart Failure, Renal FailureRisk Factors (RF): additional RF (smoking, TC > 6.5 mmol/L, family history of premature vascular disease) Clinicalatherosclerosis (CHD, carotid stenosis, peripheral vascular disease, TIA, stroke)MI: Mycardial Infarction
Green Yellow Orange RedLegend:
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N5
HY
PE
RTE
NS
ION
AN
DD
IAB
ETE
S
02.Layout 10/18/10 12:50 PM Page 66
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
67
Slide 11
THERAPEUTICS LIFESTYLE MODIFICATION-DIETARY COUNSELING
• Dietary counseling should be targeted to: - Achieve an optimal body weight- Achieve an agreed glycaemic control- Manage concomitant dyslipidaemia
• Moderate dietary sodium restriction to enhance the effects of BP lowering drugs especially ACEIs and ARBs
• Further sodium restriction, with or without a diuretic, may be necessary in the presence of nephropathy or when the BP is difficult to control
Slide 12
THERAPEUTICS LIFESTYLE MODIFICATION-REGULAR PHYSICAL EXERCISE
• General advice on cardiovascular health would be for “milder” exercise, such as brisk walking for 30 – 60 minutes at least 3 times a week
Slide 13
DISCUSSION POINT 3
• Would you commence antihypertensive agent?• Which antihypertensive agent would you choose and why?• What is his target blood pressure?• How soon would you see him again?
Slide 14
PHARMACOLOGICAL MANAGEMENT
• Pharmacological treatment should be initiated when:1. The BP is persistently > 130/80 mmHg
or2. There is a presence of microalbuminuria or overt proteinuria even if the BP is not
elevated
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N5
HY
PE
RTE
NS
ION
AN
DD
IAB
ETE
S
02.Layout 10/18/10 12:50 PM Page 67
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
68
Slide 15
CHOICE OF ANTIHYPERTENSIVES
• Certain classes of antihypertensive drugs may compromise diabetic control & aggravate its complications
Drugs Adverse
Diuretics 1. High doses will decrease insulin responsiveness2. Dyslipidaemia
ß-blockers 1. Masking of early symptoms of hypoglycaemia2. Slowing of recovery from hypoglycaemia3. Aggravation of symptoms of peripheral vascular disease4. Dyslipidaemia
Peripheral β-blockers / 1. Worsening of orthostatic hypertensionCentrally acting drugs
Slide 16
ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIs)
1. Drugs of choice based on extensive data attesting to their cardiovascular and renal protective effects in diabetic patients
2. In addition they do not have adverse effects on lipid and carbohydrate metabolism3. If an ACEI is not tolerated, an ARB should be considered
Slide 17
ANGIOTENSION RECEPTOR BLOCKERS (ARBs)
1. Reported to be superior to conventional non-ACEI antihypertensive drugs in slowing the progress of diabetic nephropathy at both the i. microalbuminuric stage andii. overt nephropathy stage
2. They have been shown to be of similar efficacy as ACEIs but better tolerated 3. There have been no reports of adverse effects on carbohydrate and lipid metabolism
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N5
HY
PE
RTE
NS
ION
AN
DD
IAB
ETE
S
02.Layout 10/18/10 12:50 PM Page 68
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
69
Slide 18
DIURETICS
1. Can be added on when monotherapy is inadequate2. The lowest possible dose should be used to minimise adverse metabolic effects3. Adverse metabolic effects from higher doses have been reportedly reduced when used
in combination with an ACEI or an ARB
Slide 19
CALCIUM CHANNEL BLOCKERS (CCBs)
1. Can be added on when monotherapy is inadequate2. Do not have significant adverse metabolic effects or compromise diabetic control3. Nondihydropyridine CCBs may be more superior to dihydropyridine CCBs in reducing
proteinuria in diabetic nephropathy
Slide 20
β-BLOCKERS & PERIPHERAL α-BLOCKERS
1. ß-blockers may be used when ACEIs, ARBs or CCBs cannot be used or when there are concomitant compelling indications
2. Peripheral α-blockers do not have adverse effects on carbohydrate or lipid metabolismbut orthostatic hypotension due to autonomic neuropathy may be aggravated
Slide 21
TARGET BLOOD PRESSURE
• Tight BP control should take precedence over the class of antihypertensive drug used • The BP should be targeted to < 130/80 mmHg• There are suggestions that a lower target BP may be necessary to maximally protect
against the development and progression of cardiovascular and renal disease • The BP should be lowered even further to < 125/75 mmHg in the presence of
proteinuria of > 1 g/24 hours
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N5
HY
PE
RTE
NS
ION
AN
DD
IAB
ETE
S
02.Layout 10/18/10 12:50 PM Page 69
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
70
Slide 22
RECOMMENDATIONS
1. ACEIs are the agents of choice for patients with diabetes without proteinuria2. ACEIs or ARBs are the agents of choice for patients with diabetes and proteinuria3. ß-blockers, diuretics or CCBs may be considered if either of the above cannot be used
Slide 23
BLOOD PRESSURE TREATMENT TARGETS
Category Target blood pressure (mmHg)
Uncomplicated HPT < 140/90
Hypertension in high risk groups < 130/80
Diabetics with proteinuria of (> 1 g/24 hours) < 125/75
Once target BP is achieved, follow-up at 3-6 month interval is appropriate.
Slide 24
VISIT 1: SUMMARY OF MANAGEMENT PLAN FOR MR. LM’S HYPERTENSION
1. Explain regarding the diagnosis of hypertension, its contribution of risk to diabetic complications2. Educate regarding the need of BP treatment, target of < 130/80 mmHg, choice of
medication, potential heart & kidneys protection vs. side effects3. Empower patient to self-manage through diet and exercise, home monitoring of sugar & BP4. Commence ACEI as single antihypertensive agent5. Arrange renal profile to be done within 2 weeks6. Review after 1 month
Slide 25
VISIT 2: FOLLOW UP AT 1 MONTH LATER
• Feeling very well generally, no new complaint• No side effect of ACEI or insulin• Had visited the ophthalmologist, reply letter stated he has immature cataract and
moderate to severe non-proliferative diabetic retinopathy in both eyes, laser therapy done, and follow-up in 3 months
• Still taking 4 meals in the factory cafetaria but able to keep ONE teh tarik a day, and reduced some oily & salty food as he claimed he cannot control the menu
• Started to walk 20 to 30 minutes around his neighborhood every weekend
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N5
HY
PE
RTE
NS
ION
AN
DD
IAB
ETE
S
02.Layout 10/18/10 12:50 PM Page 70
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
71
Slide 26
VISIT 2: FURTHER INFORMATION
• Home glucose monitoring 5 – 8 mmol/L• Home BP monitoring 120 - 130/80 - 90 mmHg• BMI and WC – no change • BP in the clinic 130/80 mmHg• Renal profile was normal• Fasting blood sugar 6 mmol/L• Urine protein 1+
Slide 27
DISCUSSION POINT 4
• What is the state of his BP control?• How would you manage Mr. LM at this stage?• What is your next step of action?
Slide 28
VISIT 2: FURTHER MANAGEMENT FOR MR. LM
• Inform him that his treatment target < 130/80 mmHg is still not achieved• Set personalized treatment goals with him
– Increase walking to 30 min three times a week– Reduce outside food to 2 times per day to control oil & salt intake– BP monitoring at least twice per week targeting < 130/80
• Emphasize on low salt diet & praise him for walking every weekend• Increase the dose of ACEI or add a low dose diuretics
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N5
HY
PE
RTE
NS
ION
AN
DD
IAB
ETE
S
02.Layout 10/18/10 12:50 PM Page 71
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
72
Slide 29
VISIT 2: FURTHER MANAGEMENT FOR MR. LM
• Plan to review after 1 month– If well-controlled – continue treatment, review 3-6 monthly– If uncontrolled – check adherence, change/adjust medications 2 to 4 weekly till
target achieved• Inform & emphasize needs for long-term follow up• Educate importance of
– CV risks assessment annually– Complication assessment 6-monthly
Slide 30
KEY LEARNING POINTS
• About 2 in 5 people with recently diagnosed diabetes will have hypertension• About 1 in 2 patients will have hypertension before the diagnosis of microalbuminuria • Antihypertensive should be initiated when the BP is persistently > 130/80 mmHg or there
is microalbuminuria / proteinuria• ACEIs / ARBs are the agents of choice for patients with diabetes• The BP should be targeted to < 130/80 mmHg or to < 125/75 mmHg if the proteinuria
> 1 g/24 hours
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N5
HY
PE
RTE
NS
ION
AN
DD
IAB
ETE
S
02.Layout 10/18/10 12:50 PM Page 72
02.Layout 10/18/10 12:50 PM Page 73
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
74
Slide 1
• Mr. AH• 50 years old• Male
• Married with 4 children
• Food hawker
REVIEW VISIT 1
• Came to the clinic for routine review of blood pressure
• On ß-blocker and thiazide diuretic• Smoker – 20 cigarettes a day• Otherwise well, no significant past medical history• BMI 30 kg/m2, Waist Circumference (WC) 98 cm• BP 152/90 mmHg, other examinations – normal• FBS 5.8 mmol/l, Renal Profile normal• TC 6.7, TG 2.6, HDL 1.3, LDL 3.4 (all in mmol/litres)
Slide 2
DISCUSSION POINT 1
• What is the diagnosis?• What is the target blood pressure?• Comment on his current medication.• How do you manage this patient?• How do you explain your plan to the patient?
Slide 3
METABOLIC SYNDROME DIAGNOSIS
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N6
HY
PE
RTE
NS
ION
AN
DM
ETA
BO
LIC
SY
ND
RO
ME
Case 6
02.Layout 10/18/10 12:50 PM Page 74
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
75
Slide 4
BLOOD PRESSURE TREATMENT TARGETS
Category Target blood pressure (mmHg)
Uncomplicated HPT < 140/90
Hypertension in high risk groups < 130/80
Diabetics with proteinuria of (> 1 g/24 hours) < 125/75
Once target BP is achieved, follow-up at 3-6 month interval is appropriate.
Slide 5
CHOICE OF PHARMACOTHERAPY
ß-blockers and thiazide diuretics have the potential to increase the incidence of newonset diabetes, and this should be taken into consideration when choosing drugs forpatients diagnosed with Metabolic Syndrome.
Slide 6
REVIEW VISIT 1: SUMMARY OF MANAGEMENT PLAN
• Explain to him that he has Metabolic syndrome and the significance of the diagnosis inrelation to CV risks. Explain that his BP is still not controlled (target < 130/80 mmHg)
• Discuss lifestyle modifications e.g. exercise, diet and weight reduction• Discuss about his medication and explain that it is unsuitable for his condition. Discuss
changing his medication to ACE Inhibitor or CCB• Commence him on statin• Arrange for Renal Profile (RP), FSL, LFT, ECG and urinalysis• Arrange for a follow up in 3 months
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N6
HY
PE
RTE
NS
ION
AN
DM
ETA
BO
LIC
SY
ND
RO
ME
02.Layout 10/18/10 12:50 PM Page 75
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
76
Slide 7
REVIEW VISIT 2
• Mr. AH came for follow up after 3 months• Tried to do more walking• Still smoking – not ready to stop• Tried to cut down on salt and fried food but finding it difficult because he works as a
food hawker• Mother aged 75 has Hypertension and Diabetes Mellitus. Father died at 65 with MI• Has been taking Perindopril 8mg once daily and Simvastatin 40 mg once daily as
prescribed in the last visit – there is no side effect• BP 142/86 mmHg, BMI 30 kg/m2, WC 97cm• TC 5.2, TG 1.6, HDL 1.3, LDL 2.4 (all in mmol/litres)• RP, LFT, ECG and urinalysis normal
Slide 8
DISCUSSION POINT 2
• How do you manage this patient at this stage?
Slide 9
REVIEW VISIT 2: SUMMARY OF MANAGEMENT PLAN
• Re-emphasize the significance of having Metabolic Syndrome in relation to his CV andDM risk factors
• Educate regarding BP control – target still not achieved• Educate regarding FSL reading – target now achieved• Re-emphasize self-management through lifestyle modification (no change in BMI or WC
after 3 months)• Consider adding Calcium Channel Blocker (CCB)• Continue statin• Discuss referral to a dietician• Arrange follow up in 3 months
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N6
HY
PE
RTE
NS
ION
AN
DM
ETA
BO
LIC
SY
ND
RO
ME
02.Layout 10/18/10 12:50 PM Page 76
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
77
Slide 11
DISCUSSION POINT 3
• Discuss the factors which may prevent this patient from achieving targets (weight/ BP)• Discuss the factors which may motivate the patient to change• What else can we do to help the patient?
Slide 10
THERAPEUTIC LIFESTYLE MODIFICATION
Weightreduction
As far as possible aim for an ideal Body Mass Index [Weight(kg)/Height2 (m)] – for Asians, the normal range has been proposedto be 18.5 to 23.5 kg/m2. However a weight loss as little as 4.5 kgsignificantly reduces BP
Salt intake
An intake of < 100 mmol of sodium or 6g of sodium chloride aday is recommended (equivalent to < 1 1/4 teaspoonfuls of salt or3 teaspoonfuls of monosodium glutamate)
Alcohol intake
Standard advice is to restrict intake to no more than 21 units formen and 14 units for women per week (1 unit equivalent to 1/2 apint of beer or 100 ml of wine or 20 ml of proof whisky)
Physical activity
General advice on cardiovascular health would be for “milder”exercise, such as brisk walking for 30 – 60 minutes at least 3times a week
DietA diet rich in fruits, vegetables and dairy products with reducedsaturated and total fat can substantially lower BP (11/6 mmHg inhypertensive patients and 4/2 mmHg in patients with high normal BP)
Smoking cessation
Cessation of smoking is important in the overall management ofthe patients with hypertension in reducing cardiovascular risk
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N6
HY
PE
RTE
NS
ION
AN
DM
ETA
BO
LIC
SY
ND
RO
ME
02.Layout 10/18/10 12:50 PM Page 77
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
78
Slide 12
REVIEW VISIT 3
• Mr. AH brings along his wife who wants to help him. She is afraid of losing him• Has been doing more exercise at home by walking to the local shops to get the newspaper • His wife is trying to cook healthier meals• Now smokes 15/day• No side effect with ACE Inhibitor, CCB or Statin• BP checked 130/80 mmHg• Lost 2 kg since last appointment• He’s happy with his progress• Still waiting for his appointment with dietician
Slide 13
REVIEW VISIT 3: SUMMARY OF MANAGEMENT PLAN
• Continue to give encouragement and motivation for his positive lifestyle changes• Get his wife involved in giving him encouragement and support• Chase up his dietician appointment• If BP remain controlled, continue with 3-6 monthly follow up• Review his CV and DM risks annually
Slide 14
SUMMARY OF EVIDENCE
Metabolic Syndrome is a cluster of risk factors predisposing to CV disease and Diabetes.A person with Metabolic syndrome is twice likely to develop heart disease and five timesmore likely to develop DM. Various components of Metabolic Syndrome should be treatedseparately.
Slide 15
KEY LEARNING POINTS
• Metabolic syndrome is a cluster of risk factors predisposing to CV disease and DM• Hypertension in Metabolic Syndrome must be treated aggressively to lower the risk.
Target BP < 130/80 mmHg• Thiazide diuretics and β-blockers are found to increase incidence of developing DM in
Metabolic Syndrome• Therapeutic lifestyle changes is key to patient management and achieving targets • It is important to treat all of the variables in Metabolic Syndrome independently
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N6
HY
PE
RTE
NS
ION
AN
DM
ETA
BO
LIC
SY
ND
RO
ME
02.Layout 10/18/10 12:50 PM Page 78
02.Layout 10/18/10 12:50 PM Page 79
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
80
Slide 1
• Mr. M• 53-year-old• Male
VISIT 1
• Was referred back to you from hospital with the following diagnoses:- Hypertensive heart disease- Left ventricular hypertrophy- Hypercholesterolaemia
Slide 2
VISIT 1
• These were the list of medications he was discharged with:- Losartan 50 mg OM- Simvastatin 40 mg ON- HCT 12.5 mg OM- Atenolol 50 mg OM
• The letter stated that: “kindly follow up and do the needful” • The patient expected you to prescribe the medication for him.
Slide 3
DISCUSSION POINT 1
• What would be your aims in this consultation in relation to hypertension management?• How would you tell him?
Slide 4
TIPS FOR DISCUSSION POINT 1
• Try to have an outline for your points and be clear of the reasons for your points• Write down your answer, you don’t have to write down your name. Discuss you answer
with the person you are comfortable with. • Tell us your answer once you are ready
(10 minutes)
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N7
HY
PE
RTE
NS
ION
AN
DC
AR
DIO
VAS
CU
LAR
DIS
EA
SE
Case 7
02.Layout 10/18/10 12:50 PM Page 80
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
81
Slide 5
WHAT WOULD BE YOUR AIMS IN THIS CONSULTATION IN RELATION TOHYPERTENSION MANAGEMENT?
1. Assess any other target organ damageThe referral letter stated that he has hypertensive heart disease. Hence it is likely that he may suffer from various vascular related diseases like:
Ischaemic heart disease Stroke
Left ventricular hypertrophy Peripheral vascular disease
Heart failure Renal disease, secondary renal artery stenosis
Hypertensive vascular disease is a multi-organ disease. Many systems could be affected by HPT.
Slide 6
WHAT WOULD BE YOUR AIMS IN THIS CONSULTATION IN RELATION TOHYPERTENSION MANAGEMENT?
2. Check for target control: BP < 130/80 mmHg, and other CVD risk factors
Risk factors
Smoking
Wt
Waist circumference
Diet
Exercise
Cholesterol/DM
Targets
Abstinence
BMI chart ideally < 23 kg/m2
Male < 90 cm, Female < 80 cm
Low salt and possibly low cholesterol diet
30 minutes 3-5 times/day
See relevant CPG
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N7
HY
PE
RTE
NS
ION
AN
DC
AR
DIO
VAS
CU
LAR
DIS
EA
SE
Slide 7
WHAT WOULD BE YOUR AIMS IN THIS CONSULTATION IN RELATION TOHYPERTENSION MANAGEMENT?
3. Assess for suitability/adherence of medications Essentially covers:i. Side-effectsii. Co-morbiditiesiii. Psycho-social issues related to treatment of HPT
02.Layout 10/18/10 12:50 PM Page 81
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
82
Slide 8
WHAT WOULD BE YOUR AIMS IN THIS CONSULTATION IN RELATION TOHYPERTENSION MANAGEMENT?
1. Assess any other target organ damage2. Check for target control3. Assess for suitability/adherence of medications 4. Self-management plan and holistic care (will not be discussed in details)
Slide 9
DISCUSSION POINT 2
• For each of these aims below (or your own aims), what are your actions?1. Target organ damage assessment2. Target BP control assessment3. Assessment of optimal medication/adherence
• What is your next step of action?
Slide 10
HISTORY TAKING: ASK FOR
1. Symptoms of IHD, heart failure: NYHA class, claudication, history of stroke and admission
2. Any consultation with specialist care and what care has he been receiving?3. How has he been with the control of HPT, is he aware of his blood pressure and any
form of home blood pressure monitoring?4. Any side effects from the medication, any problems (including personal preferences,
disruption of daily routine) in taking the medication?
Slide 11
PHYSICAL EXAMINATIONS
1. Observe: gait (remember the neurological complication)2. Body mass index, waist circumference3. BP, pulse (including peripheral pulses: remember to check this to detect underlying PVD;
ß-blocker effect)4. Signs of end-organ damage: e.g. heart failure etc
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N7
HY
PE
RTE
NS
ION
AN
DC
AR
DIO
VAS
CU
LAR
DIS
EA
SE
02.Layout 10/18/10 12:50 PM Page 82
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
83
Slide 12
INVESTIGATIONS
1. ECG: to look for features of LVH, IHD 2. Urine protein, KIV quantification of urine protein3. Blood: renal profile, cholesterol, fasting blood sugar level4. CXR (if it is not done)5. Further referral to cardiologist for assessment
Slide 13
VISIT 1: FURTHER HISTORY
• Mr. M had been having HPT for 15 years• He had not been regular with his medication apparently because of frequent traveling as
a businessman• He ended up in the hospital because of minor cuts he sustained while doing some
carpentry work at home and was subsequently noted to have uncontrolled blood pressure• His effort tolerance had been good• Quick dietary assessment did not reveal any significant issue. He exercised regularly
Slide 14
VISIT 1: PHYSICAL EXAMINATIONS
• BMI = 26 kg/m2 WC = 105 cm• BP 142/94 mmHg• PR 56 bpm• Right dorsalis pedis pulse was difficult to palpate • No sign of heart failure/cardiomegaly• You had a good look at the ankle (Do you know
the reason for examining the ankle?)
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N7
HY
PE
RTE
NS
ION
AN
DC
AR
DIO
VAS
CU
LAR
DIS
EA
SE
02.Layout 10/18/10 12:50 PM Page 83
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
84
Slide 15
VISIT 1: INVESTIGATIONS
• The levels of blood urea and serum creatinine were normal, K+ = 4.8 mmol/L• Fasting blood sugar = 5.3 mmol/L• Urine dipstix: normal reading for protein, no cell/cast was noted• Cholesterol profile:• TC 5.7 mmol/L HDL-C 0.9 mmol/L• TG 1.8 mmol/L LDL-C 3.6 mmol/L• ECG (next slide)
Slide 16
Slide 17
HE WAS OBVIOUSLY NOT TREATED TO TARGET
• What are his target?
Parameters
BP
LDL-C (as the primary target)
BMI
WC
Targets
< 130/80 mmHg
3.4 mmol/L
< 23.0 kg/m2
< 90 cm
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N7
HY
PE
RTE
NS
ION
AN
DC
AR
DIO
VAS
CU
LAR
DIS
EA
SE
02.Layout 10/18/10 12:50 PM Page 84
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
85
Slide 18
DISCUSSION POINT 3
• What is your diagnosis for him now?• Would you alter his medication or continue the same regime? Give reason.
Slide 19
WHAT IS YOUR DIAGNOSIS FOR HIM NOW?
• HPT: suboptimal control• Left ventricular hypertrophy• Hypercholesterolaemia• Possibility of peripheral vascular disease • Problems with adherence
Slide 20
WOULD YOU ALTER HIS MEDICATION OR CONTINUE THE SAMEREGIME? GIVE REASON
• He was given these medications from the hospital:1. Losartan 50 mg OM2. Simvastatin 40 mg ON3. Hydrochlorothiazide (HCT) 12.5 mg OM4. Atenolol 50 mg OM
• You were stuck and not sure which is the best. Suddenly, you thought of referring to the CPG on HPT.
Slide 21
RECOMMENDATIONS
• Hypertensive patients with LVH should receive an ARB as the first line treatment• In CHD, β-blockers, ACEIs and long acting CCBs are the drugs of choice• β-blockers, ACEIs, and aldosterone antagonists should be considered in patients
with CHD especially in post myocardial infarction and when associated with LV dysfunction
• β-blockers need to be cautiously used in patients with peripheral vascular disease. • They are contraindicated in patients with severe PVD• Diuretics, ACEIs, β-blockers, ARBs, and aldosterone antagonists are drugs of choice
for heart failure.• ARB is indeed the correct choice• β-blockers may not be a suitable choice for him!
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N7
HY
PE
RTE
NS
ION
AN
DC
AR
DIO
VAS
CU
LAR
DIS
EA
SE
02.Layout 10/18/10 12:50 PM Page 85
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
86
Slide 22
PHARMACOLOGICAL MANAGEMENT
Choice of Hypertensive drugs in patients with concomitants conditions
• Diuretic is also the correct choice
Slide 23
DISCUSSION POINT 4
• What will be the best choice then?
Slide 24
WHAT WILL BE THE BEST CHOICE THEN?
• Perindopril (ACE-I) 2 mg (has to re-start the regime as he has not been taking Losartan)• HCT 12.5 mg OM• Simvastatin 80 mg ON• Felodipine 5 mg OM (explore the option of fixed dose combinatio therapy)
Slide 25
KEY LEARNING POINTS
• The cardiovascular complications of HPT signify a long standing hypertension and possibly have other target organ damage
• There are a wide range of choices for anti-hypertensives• Appropriate choice of anti-hypertensive medication depends in co-morbidities and
complications, taking into consideration patient’s perspective• Cost and side-effect can be a significant determinants
Concomitant disease Diuretics β-blockers ACEIs CCBs Peripheral α-blockers ARBs
Coronary heart disease + +++ +++ ++ + ++
Heart failure +++ +++# +++ +@ + +++
Asthma + - + + + +
Peripheral vascular disease + +/- + + + +
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N7
HY
PE
RTE
NS
ION
AN
DC
AR
DIO
VAS
CU
LAR
DIS
EA
SE
02.Layout 10/18/10 12:50 PM Page 86
02.Layout 10/18/10 12:50 PM Page 87
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N(3
rdE
dit
ion
)T
RA
ININ
GM
OD
UL
EF
OR
HE
ALT
HC
AR
EP
RO
VID
ER
S
88
Slide 1
• Mr. AK• 58 years old• Male
• Married with 5 grand children
• Retired teacher
VISIT 1
• Brought to the clinic by his son on a wheel chair• Developed right sided weakness and slurred
speech since 5 am today
Slide 2
VISIT 1: FURTHER INFORMATION
• No vomiting, headache, fever, blurred vision, fits, incontinence• No history of injury• Known to have hypertension for 10 years• Defaulted treatment since the last 5 years and is currently not on any medication• Smokes 20 cigarettes a day• BP 210/100 mmHg, slurred speech, orientated to time, place and person• Right side UL/LL: Power 3+/5, tone normal, reflexes normal• Plantar equivocal• Cardiovascular and chest examinations – unremarkable
Slide 3
DISCUSSION POINT 1
• What is the diagnosis?
INT
ER
AC
TIV
EC
AS
ED
ISC
US
SIO
N8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
Case 8
02.Layout 10/18/10 12:50 PM Page 88
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
89
Slide 4
SEVERE HYPERTENSION
Severe hypertension is defined as BP > 180/110mm Hg(persistent elevation after 30 minutes bed rest)
Asymptomatic severeHPT• Incidental findings• Non-specific
symptoms likeheadache, dizziness,lethargy
Management• Most can be managed
as outpatient• Review existing drug
regime andcompliance
• For newly-diagnosed,consider admissionfor evaluation
• For established HPT,admit if complianceremains a problem
Hypertensiveurgencies• Presents with grade III
or IV retinal changes,or proteinuria ≥ 2+, butno overt organ failure
Management• Initial treatment
should aim for 25%reduction in BP over24 hours but notlower than 160/90mmHg
• Combination therapyis often necessary(see table below)
• Admit patient if BPremain > 180/110mmHg
Hypertensiveemergencies• Presents with
symptoms and signsof TOC e.g. acuteheart failure,subarachnoidhaemorrhage, acutecoronary syndromes
Management • All patient should be
admitted• Aim to reduce BP by
25% over 3-12 hoursbut not lower than160/90 mmHg
• Best achieved withparenteral drugs
Possible clinical scenarios
Slide 5
MANIFESTATIONS OF TOD/TARGET ORGAN COMPLICATION (TOC)
Cardiac
Cerebrovascular
Peripheralvasculature
Renal
Retinopathy
Organ System Manifestations
Left ventricular hypertrophy (LVH), coronary heart disease (CHD),heart failure
Transient ischaemic attack (TIA), stroke
Absence of one or more major pulses in extremities (exceptdorsalis pedis) with or without intermittent claudication
GFR < 60ml/min/1.73m2, proteinuria (≥1+), microalbuminuria (2 outof 3 positive tests over a period of 4-6 months)
Haemorrhages or exudates, with or without papilloedema
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 89
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
90
Slide 6
COMMON CAUSES OF SEVERE HYPERTENSION*
Slide 7
HYPERTENSION AND STROKE
Blood pressure is the most consistent and powerful predictor of stroke and high bloodpressure is the most important modifiable cause of stroke. BP levels are continouslyassociated with the risk for stroke. Although both SBP and DBP are associated with stroke,SBP is more predictive. In the Asia Pacific region, up to 66% of stroke can be attributed tohypertension.
Slide 8
DISCUSSION POINT 2
• How would you manage the patient?• How would you explain your plan to him and his son?
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 90
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
91
Slide 9
SEVERE HYPERTENSION
Severe hypertension is defined as BP > 180/110 mmHg(persistent elevation after 30 minutes bed rest)
Asymptomatic severeHPT• Incidental findings• Non-specific
symptoms likeheadache, dizziness,lethargy
Management• Most can be managed
as outpatient• Review existing drug
regime andcompliance
• For newly-diagnosed,consider admissionfor evaluation
• For established HPT,admit if complianceremains a problem
Hypertensiveurgencies• Presents with grade III
or IV retinal changes,or proteinuria ≥ 2+, butno overt organ failure
Management• Initial treatment
should aim for 25%reduction in BP over24 hours but notlower than 160/90mmHg
• Combination therapyis often necessary(see table below)
• Admit patient if BPremain > 180/110 mmHg
Hypertensiveemergencies• Presents with
symptoms and signsof TOC e.g. acuteheart failure,subarachnoidhaemorrhage, acutecoronary syndromes
Management • All patient should be
admitted• Aim to reduce BP by
25% over 3-12 hoursbut not lower than160/90 mmHg
• Best achieved withparenteral drugs
Possible clinical scenarios
Slide 10
TREATMENT OF HYPERTENSION IN ACUTE STROKE
Recommendations• Lowering blood pressure is the key to both primary and secondary prevention of stroke• In acute stroke, lowering BP is best avoided in the first few days unless hypertensive
emergencies co-exist• In primary prevention, the benefits of BP lowering is seen in both normotensive and
hypertensive patients• ACEI- or ARB- based treatment is preferred in secondary prevention
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 91
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
92
Slide 11
TREATMENT OF HYPERTENSION IN ACUTE STROKE
Treatment of elevated BP in acute stroke is still controversial. In general, it is best to avoidlowering BP in the first few days after a stroke unless there is evidence of accelerated
hypertension or patients presenting concurrently with hypertensive emergencies.
Recommendations• Lowering blood pressure is the key to both primary and secondary prevention of stroke• In acute stroke, lowering BP is best avoided in the first few days unless
hypertensive emergencies co-exist• In primary prevention, the benefits of BP lowering is seen in both normotensive and
hypertensive patients• ACEI- or ARB- based treatment is preferred in secondary prevention
Slide 12
TREATMENT OPTIONS FOR HYPERTENSIVE EMERGENCIES (PARENTERAL)
Slide 13
VISIT 1: SUMMARY OF MANAGEMENT PLAN FOR MR. AK
• Explain the diagnosis to the patient and his son – Hypertensive Emergency presentingwith Stroke (Right Hemiparesis)
• Explain the importance of hospital admission and the importance of confirming thetype of stroke (haemorrhagic/Infarct)
• Arrange and prepare for hospital admission:1. Secure intravenous line 2. Inform the receiving hospital3. Send by ambulance, accompanied by paramedics
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 92
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
93
Slide 14
VISIT 2: BP REVIEW
• Mr. AK came back to the clinic 1 month after being discharged from the hospital• Stable but no improvement of symptoms• Still has residual weakness of right side of body and slurred speech• Tolerating oral fluids and soft diet• Using diapers due to mobility problems but no incontinence• Appointment with physiotherapist: twice per week• Appointment with neurologist: in 4 months
Slide 15
VISIT 2: BP REVIEW
• He brought along a discharged letter from the hospital which contains the following informations:
Diagnosis: Left Cerebral InfarctCT scan of brain: Left temporo-parietal hypodense lesion. No midline shift. Findings consistent with Left Cerebral Infarct.Medications: - Hydrochlorothiazide 25 mg daily
- Perindopril 4 mg daily- Simvastatin 40 mg nocte- Aspirin 150 mg daily
Investigations: - FBS 5.5 mmol/l, Renal Profile normal.- TC 6.5, TG 2.3, HDL 0.9, LDL 4.6 (all in mmol/litres).- Liver Function Test normal- Urine Microalbumin positive- ECG: LVH - awaiting ECHO appointment
BP upon discharge – 150/90 mmHgPlease review his blood pressure
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 93
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
94
Slide 16
VISIT 2: FURTHER HISTORY
• Taken care at home by his wife and youngest daughter• Stopped smoking since incidence• Eat home-cook meal• Has been to Physiotherapy twice for mobilization exercise• Adhering to the medication given by hospital• Understand that Stroke is the complication of Hypertension• No symptoms to suggest secondary causes of hypertension
Slide 17
VISIT 2: PHYSICAL EXAMINATION FINDINGS
• BMI: 26 kg/m2
• Waist circumference (WC): 88 cm• BP: 140/90 mmHg• Fundoscopy : normal• Cardiovascular examinations - normal • Chest examinations – normal• Abdominal examinations – normal• Neurological examinations – Right side UL/LL: Power 3+/5, hypertonia, reflexes brisk,
sensation: normal• Plantar: up going
Slide 18
DISCUSSION POINT 3
• What is the level of his global CV risk stratification?• How would you manage the patient?• How do you educate the patient to prevent him from getting another stroke?• What is his target BP and cholesterol level?
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 94
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
95
Slide 10
CARDIOVASCULAR RISK STRATIFICATION
Co-existingCondition
BP Levels(mmHg)
SBP 120-139and/or
DBP 80-89Low Medium High Very High
SBP 140-159 and/or
DBP 90-99Low Medium High Very High
SBP 160-179 and/or
DBP 100-109Medium High Very High Very High
SBP 180-209 and/or
DBP 100-119High High Very High Very High
SBP ≥ 210 and/or
DBP ≥ 120Very High Very High Very High Very High
No RFNo TODNo TOC
TOD orRF (1-2),No TOC
TOD or RF (≥ 3) or Clinicalatherosclerosis
Previous MI orPrevious Stroke
or DiabetesMellitus (DM)
Risk Level Risk of major CV event in 10 years Management
Low < 10% Lifestyle changes
Medium 10-20% Drug treatment and lifestylechanges
High 20-30% Drug treatment and lifestylechanges
Very High > 30% Drug treatment and lifestylechanges
TOD : LVH, Retinopathy, Proteinuria / TOC : Heart Failure, Renal FailureRisk Factors (RF): additional RF (smoking, TC > 6.5 mmol/L, family history of premature vascular disease) Clinicalatherosclerosis (CHD, carotid stenosis, peripheral vascular disease, TIA, stroke)MI: Mycardial Infarction
CV Risk level is calculated based on his untreated BP
Green Yellow Orange RedLegend:
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 95
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
96
Slide 20
TABLE 3. CARDIOVASCULAR RISK FACTORS
Major risk factors√ Hypertension
Cigarette Smoking Central obesity (waist circumference > 90 cm for men, > 80 cm for women)
√ Physical inactivity√ Dyslipidaemia
Diabetes mellitus√ Microalbuminuria
Estimated GFR* < 60 mL/min√ Age (> 55 years for men, > 65 years for women)
Family history of premature cardiovascular disease (men < 55 years or women < 65 years)
Target Organ DamageHeart Brain√ • Left ventricular hypertrophy √ • Stroke or transient ischemic attack
• Angina or prior myocardial infarction Chronic kidney disease• Prior coronary revascularisation Peripheral arterial disease• Heart failure Retinopathy
*GFR, glomerular filtration rate
Slide 21
THERAPEUTIC LIFESTYLE MODIFICATION
Therapeutic lifestyle modification is the first line treatment in all patients with Hypertension
Weightreduction
Aim for an ideal BMI (<23 kg/m2) or ideal wt (<66.5 kg). However aweight loss as little as 4.5 kg significantly reduces BP
Salt intake
An intake of < 100 mmol of sodium or 6 g of sodium chloride aday is recommended (equivalent to < 1 1/4 teaspoonfuls of salt or3 teaspoonfuls of monosodium glutamate)
Alcohol intake
Standard advice is to restrict intake to no more than 21 units formen and 14 units for women per week (1 unit equivalent to 1/2 apint of beer or 100 ml of wine or 20 ml of proof whisky)
Physical activity
General advice on cardiovascular health would be for “milder”exercise, such as brisk walking 30 mins daily
DietA diet rich in fruits, vegetables and dairy products with reducedsaturated and total fat can substantially lower BP (11/6 mmHg inhypertensive patients and 4/2 mmHg in patients with high normal BP)
Smoking cessation
Cessation of smoking is important in the overall management ofthe patients with hypertension in reducing cardiovascular risk
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 96
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
97
Slide 22
SECONDARY PREVENTION OF STROKE
• BP lowering has been shown to reduce the risk of subsequent strokes• “ACEI + diuretic” has been shown to reduce stroke recurrence• ARBs lower the morbidity and mortality from further strokes
Slide 23
BLOOD PRESSURE TREATMENT TARGETS
Category Target blood pressure (mmHg)
Uncomplicated HPT < 140/90
HPT in high risk groups: DM, History of CVD < 130/80
Diabetics with proteinuria of (> 1 g/24 hours) < 125/75
Once target BP is achieved, follow-up at 3-6 month interval is appropriate.
Slide 24
TARGET LDL- C LEVELS
* Almost all individuals with 0-1 risk factor have a 10 year risk < 10%, thus 10 year risk assessment in there individials with 0-1 risk factor is not necessary.
** These include individuals with multiple risk factors but a 10 year risk of CHD of < 20%
*** After 8-12 weeks of TLC
StrokeStroke is the 3rd leading cause of mortality in Malaysia. Evidence for the role of elevatedserum cholesterol in the pathogenesis of stroke is lacking. Fibrates and statins are safe andshould be considered in all patients presenting with strokes or transient ischaemic attacks.
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 97
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
98
Slide 25
VISIT 2: SUMMARY OF MANAGEMENT PLAN FOR MR. AK
• Educate him regarding the risk of recurrent stroke and the need to modify his very high CV risk • Educate regarding BP treatment target < 130/80 mmHg, choice of medication –
potential benefits vs side effects• Empower patient to self-manage through therapeutic lifestyle modification and self
home BP monitoring.• Continue ACE Inhibitor and Diuretic• Add another agent e.g. CCB – as his BP is still uncontrolled• Continue statin and aspirin• Monitor Renal Profile, Fasting Serum Lipid and LFT• Review monthly until target BP is achieved• Review 3 monthly once target BP is achieved• Continue long-term follow up• Assess CV risks annually
Slide 26
PRIMARY PREVENTION OF STROKE
• Trials have shown that a 10 mmHg reduction in SBP or a 5 mmHg reduction in DBP in hypertensive patient can lead to a 34% reduction in the risk of stroke.
• ß-blockers, diuretics, CCBs, ACEIs and ARBs have been shown to reduce risk and mortality of stroke.
Slide 27
SUMMARY OF EVIDENCE - HYPERTENSION AND STROKE
• Blood pressure is the most consistent and powerful predictor of stroke and high blood pressure is the most important modifiable cause of stroke
• β-blockers, diuretics, CCBs, ACEIs, and ARBs have been shown to reduce the risk and mortality of stroke
• Calcium channel blockers in particular, provided significantly better protection against stroke compared with diuretics and/or β-blockers in Asian and Caucasian populations.Combination of an ACEI and diuretics has been shown to reduce stroke recurrence in both normotensive and hypertensive patients when treatment was started at least two weeks after the stroke
• The morbidity and mortality from further strokes were also shown to be significantly lower in patients receiveing ARBs compared to CCBs for the same level of BP control
• In haemorrhagic stroke, in general, it is best to avoid lowering BP in the first few days after a stroke unless there is evidence of accelerated hypertension or patients presenting concurrently with hypertensive emergencies
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 98
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
99
Slide 28
KEY LEARNING POINTS
• Therapeutics lifestyle changes should be recommended for all individuals with HPT and pre-HPT• Blood pressure is the most consistent and powerful predictor of stroke and high blood
pressure is the most important modifiable cause of stroke• Lowering blood pressure is the key to both primary and secondary prevention of stroke• Rapid reduction of BP (within minutes to hours) in asymptomatic severe hypertension or
hypertensive urgencies is best avoided as it may precipitate ischaemic events• In primary prevention, a CCB-based therapy is preferred in secondary prevention, the
benefits of BP lowering is seen in both normotensive and hypertensive patients ACEI- orARB- based treatment is preferred in secondary prevention
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 99
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
100
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 8
HY
PE
RTE
NS
ION
AN
D S
TRO
KE
02.Layout 10/18/10 12:50 PM Page 100
02.Layout 10/18/10 12:50 PM Page 101
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
102
Slide 1
• Mr. MR• 70 years old• Male
• Married with 5 children
• Retired teacher
REVIEW VISIT 1
• Known hypertensive since 2 years, came to the clinic for follow-up
• Previous BP ranged from SBP 160-172 mmHg and DBP 74-80 mmHg
• Also has osteoarthritis of knees and constipation occasionally
• Current medication Nifedipine 10 mg tds, Diclofenac sodium 50 mg tds(prn), Ranitidine 150 mg od (prn), Lactulose syrup 15 ml ON (prn)
• On examination: alert, conscious and oriented• PR 70/min, BP 170/76 mmHg on standing and sitting• BMI 26 kg/m2
• Respiratory, Cardiovascular, GIT and CNS examinations–unremarkable
Slide 2
DISCUSSION POINT 1
• Describe the type of hypertension in this man• Comment on his BP control status• Comment on his medications• How do you explain your management plan to the patient?
Slide 3
DEFINITION OF HYPERTENSION IN THE ELDERY IS THE SAME AS INTHE GENERAL POPULATION
Optimal
Prehypertension
Stage 1 HPT
Stage 2 HPT
Stage 3 HPT
< 120
120-139
140-159
160-179
≥ 180
and
and/or
and/or
and/or
and/or
< 80
80-89
90-99
100-109
≥ 110
Diagnosis ofhypertension ismade based on theaverage of two ormore readings,taken at two ormore visits to thehealth careproviders
Category Systolic (mmHg) Diastolic (mmHg)
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 9
HY
PE
RTE
NS
ION
IN T
HE
ELD
ER
LY
Case 9
02.Layout 10/18/10 12:50 PM Page 102
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
103
Slide 5
CHOICE OF PHARMACOTHERAPY
• Five major classes of antihypertensive drugs (diuretics, β-blockers, CCBs, ACEIs and ARBs) have been shown to reduce CV events in the elderly
• In older patients with isolated systolic hypertension, diuretics are preferred because they significantly reduce multiple endpoints
Slide 4
BLOOD PRESSURE TREATMENT TARGETS
Category Target blood pressure (mmHg)
Uncomplicated HPT < 140/90
HPT in high risk groups: DM, History of CVD < 130/80
Diabetics with proteinuria of (> 1 g/24 hours) < 125/75
Once target BP is achieved, follow-up at 3-6 month interval is appropriate.
Slide 6
REVIEW VISIT 1: SUMMARY OF MANAGEMENT PLAN
• Educate Mr. MR regarding his uncontrolled systolic BP (170/76 mmHg) and its impact• Negotiate the management plan:
1. Advice on therapeutic lifestyle change – to lose weight by exercise and modest salt reduction.
2. Change his medication - stop the nifedipine, change to hydrochlorothiazide 12.5 mg once daily.
3. Arrange annual investigations to assess CV risks.4. Arrange follow-up visit within 1 month.
Slide 7
REVIEW VISIT 2
• Mr. MR came back to the clinic after 1 month• Feeling very well generally• BP checked again in this visit – 160/72 mmHg on standing and sitting • His FBS, FSL, Renal Profile, Urine Analysis and ECG were normal
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 9
HY
PE
RTE
NS
ION
IN T
HE
ELD
ER
LY
02.Layout 10/18/10 12:50 PM Page 103
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
104
Slide 8
DISCUSSION POINT 2
• Describe the blood pressure control status• Discuss the underlying reasons for his BP control status• What is your next step of action?
Slide 9
REVIEW VISIT 2: SUMMARY OF MANAGEMENT PLAN
• Educate Mr. MR that his systolic BP is still uncontrolled • Assess his adherence to treatment• Add a long-acting CCB at the lowest dose e.g. Amlodipine 5 mg od• Arrange follow up review in 1 month
Slide 10
REVIEW VISIT 3
• Mr. MR came back to the clinic after 1 month• Feeling very well generally• BP checked again in this visit – 140/68 mmHg
Slide 11
DISCUSSION POINT 3
• What is your next step of action?
Slide 12
REVIEW VISIT 3: SUMMARY OF MANAGEMENT PLAN
• Inform Mr. MR that his BP has achieved the control target • Re-emphasize lifestyle intervention• Emphasize the importance of adherence to treatment and long term follow-up• Arrange follow up every 3 months• Assess CV risks annually
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 9
HY
PE
RTE
NS
ION
IN T
HE
ELD
ER
LY
02.Layout 10/18/10 12:50 PM Page 104
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
105
Slide 13
SUMMARY OF EVIDENCE (1)
• HPT magnifies risk for CVD in the elderly compared with younger populations• SBP is a better predictor of CV events than DBP especially in the elderly• SBP increases linearly with age leading to an increase of isolated systolic hypertension
in the elderly• In patients with marked SBP and not tolerating treatment well, reducing SBP to below
160 mmHg initially is acceptable. Subsequently attempts should be made to reduce BP to target level
Slide 14
SUMMARY OF EVIDENCE (2)
• Several RCT have shown that treatment of hypertension in the elderly up to the age of 84 years reduces CV morbidity and mortality, particularly stroke
• For those > 85 years, benefit of treating hypertension prevents the fatal and debilitating consequences of hypertension such as stroke, heart failure and dementia. (HYVET TRIAL 2008)
Slide 15
SUMMARY OF EVIDENCE (3)
• Salt restriction is especially effective in the elderly due to greater sensitivity to sodium• Five major classes of antihypertensive drugs (diuretics, ß-blockers, CCBs, ACEIs and
ARBs) have been shown to reduce CV events in the elderly• In older patients with isolated systolic hypertension, diuretics are preferred because
they significantly reduce multiple endpoints
Slide 16
SUMMARY OF EVIDENCE (4)
• Several trials using CCBs have shown benefits particularly in stroke reduction• ACEi are the drugs of choice for those with concomitant left ventricular systolic
dysfunction, post MI or DM• ARBs have also been shown to reduce fatal and non-fatal strokes in hypertensive
patients aged 65 years or older
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 9
HY
PE
RTE
NS
ION
IN T
HE
ELD
ER
LY
02.Layout 10/18/10 12:50 PM Page 105
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
106
Slide 17
SUMMARY OF EVIDENCE (5)
• The starting dose of HPT medications in older patients should be at the lowest available• In order to maximise adherence, the drug regime should be as simple as possible• The elderly tend to be on polypharmacy – drug interactions should be taken into
account when considering antihypertensive treatment
Slide 18
KEY LEARNING POINTS
• The goals of treatment of hypertension in older patients should be the same as inyounger patients
• In those patients with marked SBP and not tolerating treatment well, reducing SBP tobelow 160 mmHg initially is acceptable. Subsequently, attempts should be made toreduce BP to target levels
• Weight loss and modest salt reduction are effective in the elderly because of their greatersensitivity to sodium
• Five major classes of drugs have been shown to reduce CV events in the elderly(diuretics, β-blockers, CCBs, ACEi and ARBs)
• ACEi are the drugs of choice for those with concomitant left ventricular systolicdysfunction, post MI and DM
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 9
HY
PE
RTE
NS
ION
IN T
HE
ELD
ER
LY
02.Layout 10/18/10 12:50 PM Page 106
02.Layout 10/18/10 12:50 PM Page 107
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
108
Slide 1
• Mdm NH• 35 years old
• G1P0• Housewife
VISIT 1
• Came for antenatal booking. • POA 21 weeks• UPT positive done by private GP 3 months ago• Booking BP 130/80 mmHg• Otherwise well – no other symptoms• Strong family history of hypertension• BP 140/90 mmHg• Normal physical examination
Slide 2
DISCUSSION POINT 1
• How would you manage the patient?
Slide 3
VISIT 1: SUMMARY OF MANAGEMENT PLAN FOR MDM. NH
• Explain to her that she has a raised BP (140/90 mmHg)• Explain the significance of the reading and the importance of confirming the diagnosis• Negotiate the management plan:
1. Arrange to see the nurse for E.O.D BP check for 1 week2. Arrange baseline investigations3. Advise on sign and symptoms of pre-eclampsia4. Arrange follow-up visit within 1 week
Slide 4
VISIT 2: BP REVIEW
• Mdm. NH came back to the clinic after 1 week• Feeling very well generally• BP checked by nurse over a week
– 140/90, 145/95, 140/90 mmHg• BP checked again in this visit – 140/90 mmHg• Urine albumin - nil
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
0H
YP
ER
TEN
SIO
N IN
PR
EG
NA
NC
Y
Case 10
02.Layout 10/18/10 12:50 PM Page 108
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
109
Slide 5
DISCUSSION POINT 2
• What is the diagnosis?• What is your next step of action?
Slide 6
HYPERTENSION IN PREGNANCY
Group of diseases in which hypertension is the chief clinical manifestation in pregnancy -two distinct groups:• Normotensive women who develop pre-eclampsia syndrome• Women with chronic hypertension who are at the higher risk of developing
superimposed pre-eclampsia
Slide 7
DIAGNOSIS
Mdm. NH’s BP taken ≥ 2 visits were ≥ 140/90 mmHg
Hypertension in Pregnancy is defined as a systolic blood pressure (BP) ≥ 140 mmHg and/or a diastolic BP ≥ 90 mmHg.
An increase of 15 mmHg and 30 mmHg diastolic and systolic BP levels above baseline BPis no longer recognized as hypertension if absolute values are below 140/90 mmHg.
Korotkoff V should now be used as the cut-off point for diastolic BP, and Korotkoff IVutilized only when Korotkoff V is absent.
Slide 8
BASELINE INVESTIGATIONS
• Biochemical investigations:– Platelet count, hematocrit– Serum uric acid and creatinine– Liver function test– UFEME– OGTT– 24 hour urine protein
• Other relevant investigation TRO secondary causes
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
0H
YP
ER
TEN
SIO
N IN
PR
EG
NA
NC
Y
02.Layout 10/18/10 12:50 PM Page 109
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
110
Slide 9
VISIT 2: FURTHER HISTORY
• No significant past medical history • Not on any regular medication• Both parents hypertensive• Father had heart attacks at aged 60 years• No pre-eclamptic symptoms • No symptoms to suggest secondary causes of hypertension• Sedentary lifestyle• Normal diet
Slide 10
VISIT 2: PHYSICAL EXAMINATION FINDINGS
• BP 140/90 mmHg• Normal weight gain• Fundoscopy normal• Cardiac & respiratory examinations – normal• Symphysis fundal height – 21 cm• Neurological examinations – normal
Slide 11
VISIT 2: BASELINE INVESTIGATION RESULTS
• Renal Profile: Urea 3.2 , Sodium 132, Potassium 3.5, Chloride 101 (all in mmol/L), Creatinine 65 µmol/L
• Serum uric acid: 200 µmol/L• Full Blood Count: Hb 11.5 g/dL, wbc 4500/mL, platelet 211,000/mL • OGTT: 5.3/7.0 mmol/L• Urinalysis - albumin negative
Slide 12
DISCUSSION POINT 3
• How do you classify hypertension in pregnancy? • What do you think Madam NH has?
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
0H
YP
ER
TEN
SIO
N IN
PR
EG
NA
NC
Y
02.Layout 10/18/10 12:50 PM Page 110
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
111
Slide 14
CLASSIFICATION OF HDP
1. Preeclampsia-eclampsia: clinically diagnosed in the presence of de novo hypertensionafter gestational week 20, and one or more of the following:i. Significant proteinuria.ii. Renal insufficiency: serum creatinine 90 µmol/l or oliguria.iii. Liver disease: raised transaminases and/or severe right upper quadrant or epigastric pain.iv. Neurological problems: convulsions (eclampsia), hyperreflexia with clonus or severe
headaches, persistent visual disturbances (scotoma).v. Haematological disturbances: thrombocytopenia, coagulopathy, haemolysis.vi. Fetal growth restriction.
This is followed by normalisation of the BP by three months postpartum. Oedema is nolonger part of the definition of preeclampsia. Either excessive weight gain or failure to gainweight in pregnancy may herald the onset of preeclampsia.
Slide 15
CLASSIFICATION OF HDP
2. Gestational hypertension: hypertension alone, detected for the first time after 20 weeks pregnancy. The definition is changed to “transient” when pressure normalizes postpartum.
3. Chronic hypertension: hypertension diagnosed prior to gestational week 20; or presenceof hypertension preconception, or de novo hypertension.
4. Preeclampsia superimposed on chronic hypertension:This can be diagnosed by the appearance of any of the following in a woman with chronic hypertension:i) De novo proteinuria after gestational week 20.ii) A sudden increase in the severity of hypertension.iii) Appearance of features of preeclampsia-eclampsia.iv) A sudden increase in proteinuria in women who have preexisting proteinuria early in gestation.
Slide 13
CLASSIFICATION OF HDP
HDP
Preeclamsia-eclampsia
Gestational HPT Chronic HPTPreeclampsia
superimposed onchronic HPT
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
0H
YP
ER
TEN
SIO
N IN
PR
EG
NA
NC
Y
02.Layout 10/18/10 12:50 PM Page 111
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
112
Slide 16
DISCUSSION POINT 4
• How do you manage Mdm NH?• What is your next step of action?
Slide 17
MANAGEMENT
• Early diagnosis of Hypertension in Pregnancy is vital• Recognition of Severity - mild
- severe• Colour Coding
Red Code - Mild pre eclampsia and more than 36 weeks gestation- Severe pre eclampsia- Eclampsia
Yellow Code - Mild pre eclampsia and less than 36 weeks gestation
Slide 18
VISIT 2: SUMMARY OF MANAGEMENT PLAN FOR MDM. NH
• Educate regarding the diagnosis of Hypertension in pregnancy, and potential complications• Educate regarding BP treatment target < 140/90 mmHg, choice of medication –
potential benefits vs side effects• Regular fetal and maternal surveillance• Monitor sign and symptom of impending pre-eclampsia• Empower patient to self-manage through therapeutic lifestyle modification• Address transportation problems if any• Address adverse traditional beliefs and taboos• Refer early to Obstetrician in nearest hospital for combine care
Slide 19
VISIT 3: FOLLOW UP
• Mdm. NH came for review after 2 weeks (POA 23 weeks)• Her Renal Profile was normal• Has headache and mild epigastric pain• BP checked again in this visit – 150/100 mmHg• Weight increasing • Repeat urine protein 2+
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
0H
YP
ER
TEN
SIO
N IN
PR
EG
NA
NC
Y
02.Layout 10/18/10 12:50 PM Page 112
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
113
Slide 20
DISCUSSION POINT 5
• How do you manage this lady at this stage?
Slide 21
VISIT 3: SUMMARY OF MANAGEMENT PLAN FOR MDM. NH
• Educate on her BP level – BP is high and she is symptomatic (severe pre-eclampsia)• She needs to be admitted to the hospital for BP stabilization• Perform appropriate resuscitation in the clinic before transfer
Slide 22
ANTIHYPERTENSIVE DRUGS COMMONLY USED IN PREGNANCY
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
0H
YP
ER
TEN
SIO
N IN
PR
EG
NA
NC
Y
02.Layout 10/18/10 12:50 PM Page 113
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
114
Slide 23
SEVERE PREECLAMPSIA
Must be promptly identified so that the patient can be urgently admitted to hospital for closeobservation and timely delivery. The Royal College of Obstetrician and Gynecology (RCOG)defines severe pre eclampsia as follows:1. Systolic BP 170 mmHg or diastolic BP 110 mmHg (acute hypertensive crisis in
pregnancy) on two occasions, with proteinuria of 1 g/day.2. Diastolic BP 100 mmHg on two occasions, with significant proteinuria (1+ on dipstick),
with two or more signs or symptoms of imminent eclampsia:a. severe headacheb. visual disturbancec. epigastric pain and/or vomitingd. clonuse. Papilloedemaf. liver tendernessg. platelet count below 100,000/cmm
h. abnormal liver enzymes (elevated ALT or AST)
i. HELLP syndrome (haemolysis, elevated liver enzymes, low platelets)
j. intrauterine growth restriction (IUGR)k. pulmonary oedema and/or congestive
cardiac failure
Slide 24
ANTICONVULSANTS IN PREECLAMPSIA-ECLAMPSIA
Parenteral magnesium sulphate is currently the drug of choice for the prevention of eclampsiaand to abort an eclamptic fit. The alternative is intravenous diazepam (intravenous bolus 10mg slowly over 10-15 minutes followed by infusion), bearing in mind that it is inferior in efficacycompared to magnesium sulphate.
Slide 25
POSTPARTUM CARE
• Advised to have BP checked regularly at local clinics if there is a significant delay in theirscheduled hospital follow-up
• In these patients, the dose of antihypertensive should be tailed down gradually and notstopped suddenly
• De novo onset of hypertension or aggravation of BP levels during the postpartum period,can occur
• These patients should be promptly referred to hospital especially if there is significantproteinuria. Eclampsia may occur in the postpartum period
• Chronic hypertension is diagnosed when the hypertension and/or proteinuria fails todisappear within three months postpartum
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
0H
YP
ER
TEN
SIO
N IN
PR
EG
NA
NC
Y
02.Layout 10/18/10 12:50 PM Page 114
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
115
Slide 26
KEY LEARNING POINTS
1. Preconception counseling and adjustment of treatment in women with chronic hypertension.2. Recognition of women at high risk of preeclampsia and referral in early pregnancy for
screening and prophylaxis.3. Nutritional supplementation for prevention of preeclampsia and/or its complications.4. Prevention of eclampsia and other complications of preeclampsia5. Primary care providers play an important role in preventing, detecting, monitoring
and managing preeclampsia and its complications
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
0H
YP
ER
TEN
SIO
N IN
PR
EG
NA
NC
Y
02.Layout 10/18/10 12:50 PM Page 115
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
116
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
0H
YP
ER
TEN
SIO
N IN
PR
EG
NA
NC
Y
02.Layout 10/18/10 12:50 PM Page 116
02.Layout 10/18/10 12:50 PM Page 117
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
118
Slide 1
• Puan Rahmah• 35 years old• Para 4
• Last child birth 6/12 ago
• Accountant
VISIT 1
• Referred to you for BP 150/90 mmHg after 1/12 on Combine Oral Contraceptive (COC)
• Currently not breast-feeding her child• Generally well- asymptomatic• Strong family history of hypertension
Slide 2
DISCUSSION POINT 1
• What further history would you like to elicit?• What physical examinations would you perform?• List the investigation you would do?
Slide 3
VISIT 1- FURTHER HISTORY
• Blood pressure before starting COC 130/80 mmHg• History of pregnancy induce hypertension• No symptoms of secondary causes of HPT & TOD• Unhealthy diet & sedentary lifestyle• Non smoker but husband is a chronic smoker• Not on any other medication except COC• Stressful at work and at home taking care of 4 children
Slide 4
VISIT 1- PHYSICAL EXAMINATIONS
• Repeat BP 152/90 mmHg• BMI 23 kg/m2
• Urine albumin negative, RBS 5.5 mmol/L, ECG normal
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
1H
YP
ER
TEN
SIO
N A
ND
OC
P
Case 11
02.Layout 10/18/10 12:50 PM Page 118
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
119
Slide 5
DISCUSSION POINT 2
• Discuss the patient’s problems
Slide 6
VISIT 1
Problem List• Stage 1 hypertension on COC• Passive smoker, poor diet control, sedentary lifestyle• Stressful at work and home
Slide 7
DISCUSSION POINT 3
• What would you do now?• How do you explain your plan to the patient?• Discuss alternative methods of contraception for this patient
Slide 8
VISIT 1- FURTHER ACTIONS
• Explain that she needs to stop the COC in order to control her BP• Advice and reinforce on therapeutic life-style change – diet, exercise, stress management• Closer monitoring of BP and CVD risk factors• Counsel on other methods of contraception e.g. IUCD, POP, injectable depots, implants
& barrier methods
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
1H
YP
ER
TEN
SIO
N A
ND
OC
P
02.Layout 10/18/10 12:50 PM Page 119
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
120
Slide 10
SUMMARY OF EVIDENCE
• A woman who develops hypertension while using COC should be advised to stop takingthem and should be offered alternative forms of contraception
• Blood pressure should be reviewed regularly, at least every six months
Slide 11
KEY LEARNING POINTS
• The incidence of hypertension is reported to be higher in women taking COC, especially in obese and older women
• Before started all woman on OCP the blood pressure must be check then monitored regularly while she is on OCP
• Woman who develops hypertension while using COC should be advised to stop taking them and should be offered alternative forms of contraception
• Progesterone Only Pills191 and low dose COC, recommended alternatives for patients with hypertension or develop hypertension and wish to continue with OCP
Slide 9
HYPERTENSION AND ORAL CONTRACEPTIVES
The incidence of hypertension is reported to be higher in women taking combined oralcontraceptives (COC), especially in obese and older women. The mechanism by which theBP rises is unknown. A women who develops hypertension while using COC should beadvised to stop taking them and should be offered alternative forms of contraceptions.Progesterone Only Pills and low dose COC are not known to raise BP nor increase the risks of myocardial infarction. They are recommended alternatives for patients withhypertension or those who develop hypertension and yet wish to continue oralcontraception. A prudent approach to the use of oral contraception would be to measurebaseline BP before initiating treatment. Blood pressure should be reviewed regularly, at leastevery six month.
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
1H
YP
ER
TEN
SIO
N A
ND
OC
P
02.Layout 10/18/10 12:50 PM Page 120
02.Layout 10/18/10 12:50 PM Page 121
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
122
Slide 1
• Madam OKL• 52 years old
• Married with 4 children
• Teacher
VISIT 1
• Came to the clinic for review• Was commenced on hormone replacement
therapy (HRT) - Progyluton® 2 months agowhen she presented with worsening hot flushes and vaginal dryness
• Last menstruation was about a year ago• Last blood tests were done 6 months ago (confirmed her postmenopausal status)• BP readings were between 140/90-150/94 mmHg for the past 6 months before she was
commenced on HRT
Slide 2
VISIT 1: FURTHER HISTORY
• No symptoms of CVD and TOD• Practice a prudent diet• Does regular walk every morning• Non-smoker• Taking mefenamic acid for her painful knee occasionally• Children are healthy• Parents died of ‘old age’ at 70+ years old• Living with husband
Slide 3
VISIT 1: PHYSICAL EXAMINATIONS AND BASELINE INVESTIGATIONS
ResultBMI 22 kg/m2, WC= 75 cmNeck - no goitre, no carotid bruitHeart and lung - normalAbdomen and pelvic - normalLegs - normalOther systems – normalFBG 5.5 mmol/L, Fasting serum lipid normalUrine microalbumin negativeECG normal
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
2H
YP
ER
TEN
SIO
N A
ND
HO
RM
ON
E R
EP
LAC
EM
EN
T TH
ER
AP
Y
Case 12
02.Layout 10/18/10 12:50 PM Page 122
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
123
Slide 4
DISCUSSION POINT 1
• What is the diagnosis?• What is her global CV risk stratification level?
Slide 5
DIAGNOSIS & CLASSIFICATION OF HYPERTENSION
Optimal
Prehypertension
Stage 1 HPT
Stage 2 HPT
Stage 3 HPT
< 120
120-139
140-159
160-179
≥ 180
and
and/or
and/or
and/or
and/or
< 80
80-89
90-99
100-109
≥ 110
Diagnosis ofhypertension ismade based on theaverage of two ormore readings,taken at two ormore visits to thehealth careproviders
Category Systolic (mmHg) Diastolic (mmHg)
Slide 6
CARDIOVASCULAR RISK STRATIFICATION
Co-existingCondition
BP Levels(mmHg)
SBP 120-139and/or
DBP 80-89Low Medium High Very High
SBP 140-159 and/or
DBP 90-99Low Medium High Very High
SBP 160-179 and/or
DBP 100-109Medium High Very High Very High
SBP 180-209 and/or
DBP 100-119High High Very High Very High
SBP ≥ 210 and/or
DBP ≥ 120Very High Very High Very High Very High
No RFNo TODNo TOC
TOD orRF (1-2),No TOC
TOD or RF (≥ 3) or Clinicalatherosclerosis
Previous MI orPrevious Stroke
or DiabetesMellitus (DM)
Green Yellow Orange RedLegend:
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
2H
YP
ER
TEN
SIO
N A
ND
HO
RM
ON
E R
EP
LAC
EM
EN
T TH
ER
AP
Y
02.Layout 10/18/10 12:50 PM Page 123
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
124
Slide 7
VISIT 1: FURTHER INFORMATION
• Her BP was checked again twice (15 minutes apart) on this visit: 160/100 mmHg
Slide 8
DISCUSSION POINT 2
• Summarise Mdm. OKL’s problems.• How do you manage this lady?
Slide 9
VISIT 1: SUMMARY OF PROBLEMS
• Post-menopause with persistent vasomotor symptoms• Underlying Stage 1 hypertension – worsening to Stage 2 (160/100 mmHg) since
commencing HRT• No significant co-existing CV risk factor apart from HPTIN
TE
RA
CT
IVE
CA
SE
DIS
CU
SS
ION
12
HY
PE
RTE
NS
ION
AN
D H
OR
MO
NE
RE
PLA
CE
ME
NT
THE
RA
PY
02.Layout 10/18/10 12:50 PM Page 124
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
125
Slide 10
ALGORITHM FOR THE MANAGEMENT OF HYPERTENSION
Slide 11
HYPERTENSION AND HOME REPLACEMENT THERAPY
The presence of hypertension is not a contraindication to oestrogen-based hormonalreplacement therapy (HRT). It is recommended that all women treated with HRT should havetheir BP monitored every six months. The decision to continue or discontinue HRT in thesepatients should be individualised.
The Women’s Health Initiative (WHI) trial involving 98, 705 women aged 50-79 years,concluded that the use of HRT increased cardiovascular events. Conjugated equineestrogen (CEE), alone or in combination with medroxyprogesterone acetate, was used in thestudy. In view of this, greater caution and closer monitoring is required for hypertensivepatients on CEE.
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
2H
YP
ER
TEN
SIO
N A
ND
HO
RM
ON
E R
EP
LAC
EM
EN
T TH
ER
AP
Y
02.Layout 10/18/10 12:50 PM Page 125
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
126
Slide 12
CHOICE OF PHARMACOTHERAPY
Pharmalogical management of stage 2 hypertensionInitiating therapy with the right combination of at least 2 drugs is recommended
Effective Combination
β-blockers + diuretics
β-blockers + CCBs
CCBs + ACEIs/ARBs
ACEIs + diuretics
ARBs + diuretics
Slide 14
VISIT 1: SUMMARY OF MANAGEMENT PLAN FOR MDM. OKL
• Explain to her that she has an underlying Stage 1 HPT which is now worsening.• Initiate therapy with 2 drugs e.g. CCB + ACEi• Discuss the option of continuing HRT and advise to have regular Pap smear and
mammogram• Re-emphasize on therapeutic lifestyle modification• Educate regarding potential complications, the need to start medication and her
treatment target• Review monthly until target BP is achieved• Review 3-monthly once target BP is achieved• Re-assess CV risks annually
Slide 13
BLOOD PRESSURE TREATMENT TARGETS
Category Target blood pressure (mmHg)
Uncomplicated HPT < 140/90
HPT in high risk groups: DM, History of CVD < 130/80
Diabetics with proteinuria of (> 1 g/24 hours) < 125/75
Once target BP is achieved, follow-up at 3-6 month interval is appropriate.
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
2H
YP
ER
TEN
SIO
N A
ND
HO
RM
ON
E R
EP
LAC
EM
EN
T TH
ER
AP
Y
02.Layout 10/18/10 12:50 PM Page 126
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
127
Slide 15
A NOTE ON HORMONE REPLACEMENT THERAPY-PROGYLUTON
• 11 white tab each containing Calendar pack of Oestradiol valerate 2 mg, 10 brown tab each containing Norgestrel 500 mcg, Oestradiol Valerate 2 mg
• Before starting treatment, a thorough general medical (including blood pressure measurement, urine test for sugar and, if necessary, special liver tests), andgynaecological examination (including the breasts and a cytological smear) should becarried out to detect any diseases requiring treatment or any risks and, above all, to rule out pregnancy. Control examinations are recommended at about 6-monthly intervals
• Progyluton is not a contraceptive. Where applicable contraception should be practised with non-hormonal methods
Slide 16
SUMMARY OF EVIDENCE
• The presence of hypertension is not a contraindication to oestrogen based hormonal replacement therapy (HRT)
• It is recommended that all women treated with HRT should have their BP monitored every six months
• The decision to continue or discontinue HRT in these patients should be individualized• The Women's Health Initiative (WHI) trial involving 98, 705 women aged 50-79 years,
concluded that the use of HRT increased cardiovascular events. In view of this, greater caution and closer monitoring is required for hypertensive patients on CEE
Slide 17
KEY LEARNING POINTS
• Stage 1 HPT is defined as SBP 140 and/or DBP 90 mmHg or greater, based on > 2 BP readings at > 2 clinic visits
• HRT is safe in hypertensive women. The presence of hypertension is not a contraindication to oestrogen based hormonal replacement therapy (HRT)
• Untreated or sub-optimally controlled hypertension leads to increased cardiovascular, cerebrovascular and renal morbidity and mortality
• Decision to commence pharmacological treatment should be based om global cardiovascular risks and not on the level of blood pressure (BP) per se
• All women treated with HRT should have their BP monitored every six months including regular gynaecological examination, mammogram and cervical smear
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
2H
YP
ER
TEN
SIO
N A
ND
HO
RM
ON
E R
EP
LAC
EM
EN
T TH
ER
AP
Y
02.Layout 10/18/10 12:50 PM Page 127
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
128
INT
ER
AC
TIV
E C
AS
E D
ISC
US
SIO
N 1
2H
YP
ER
TEN
SIO
N A
ND
HO
RM
ON
E R
EP
LAC
EM
EN
T TH
ER
AP
Y
02.Layout 10/18/10 12:50 PM Page 128
02.Layout 10/18/10 12:50 PM Page 129
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
130
Slide 1
GOLD STANDARD BP MEASUREMENT
• Invasive Measurement
Slide 2
MERCURY COLUMN SPHYGMOMANOMETER-GOLD STANDARD NONINVASIVE METHOD
Slide 3
STEPS TO BP MEASUREMENT
Check the machine1. The mercury meniscus – make sure it is at zero. If not, minus the baseline reading2. Inflation – deflation device
a) after 3-5 seconds of rapid inflation the mercury column should touch 200 mmHg or 40 mmHg above estimated SBP
b) ability to deflate at a rate of 2-3 mmHg per second 3. Cuff – both length and width of the bladder must be correct. The length of the bladder
must at least be 80% of the circumference of the arm and the width at least 40% the circumference of the arm
WO
RK
SH
OP
ON
BP
(BP
ME
AS
UR
EM
EN
T TE
CH
NIQ
UE
& S
KIL
LS)
02.Layout 10/18/10 12:50 PM Page 130
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
131
Slide 4
BLADDER LENGTHS
Slide 5
STEPS TO BP MEASUREMENT
• Rest the patient, back rested on the chair and arm supported at heart level, no coffee or smoking 30 minutes before
• Wrap the cuff properly• Palpate the brachial or radial artery• Inflate the bladder until the pulse disappear and inflate another 30 mmHg• Deflate the cuff slowly until the pulse is felt again (estimated SBP)• Bladder inflated to 30 mmHg above the estimated SBP
Slide 6
STEPS TO BP MEASUREMENT
• First repetitive appearance of clear tapping sound (Korotkoff 1) is SBP. Disappearance of sound (Korotkoff V) is DBP.
• If Korotkof sound does not disappear, use Korotkof 1V (muffling) • Measure on both arm at first visit. If > 20/10 mmHg is abnormal • Measure lying and standing (after 1 minute) BP for the elderly and the diabetics
WO
RK
SH
OP
ON
BP
(BP
ME
AS
UR
EM
EN
T TE
CH
NIQ
UE
& S
KIL
LS)
02.Layout 10/18/10 12:50 PM Page 131
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
132
Slide 7
CLINICAL HYPERTENSION
Slide 8
THE SPHYGMOMANOMETER
• Beware of defective machine
Slide 9
AUTOMATED SPHYGMOMANOMETER
WO
RK
SH
OP
ON
BP
(BP
ME
AS
UR
EM
EN
T TE
CH
NIQ
UE
& S
KIL
LS)
02.Layout 10/18/10 12:50 PM Page 132
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
133
Slide 10
OTHER METHODS OF MEASUREMENT
• Aneroid sphygmomanometer• Automated ambulatory BP devices• Validated by either BHS or AAMI methods
Slide 11
AMBULATORY BP
Indicated in:• suspected ‘white coat’ hypertension• borderline hypertension• labile hypertension• resistant hypertension (not controlled on 3 drugs including a diuretics)• ‘hypotensive symptoms’
Slide 12
Slide 13
DETECTING POSTURAL HYPERTENSION
• BP taken both lying and at least 1 minute standing• Significant drop: SBP ≥ 20 mmHg
WO
RK
SH
OP
ON
BP
(BP
ME
AS
UR
EM
EN
T TE
CH
NIQ
UE
& S
KIL
LS)
02.Layout 10/18/10 12:50 PM Page 133
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
134
Slide 14
MEASURING BILATERAL BP DIFFERENCES
• Difference of BP ≥ 20/10 mmHg• Consider: - Atherosclerosis
- Congenital co-arctation of aorta- Vasculitis: big vessels disease: Takayasu disease
Slide 15
AUSCULTATORY GAPS
• It is a normal phenomenon seen in elderly
Slide 16
CHANGE IN BP WITH DAILY ACTIVITIES
Meetings
Work
Transportation
Walking
Dressing
Chores
Telephone
+20
+16
+14
+12
+12
+11
+10
+15
+13
+9
+6
+10
+7
+7
Activities SBP DBP
Eating
Talking
Desk work
Reading
Television
Relaxing
Sleeping
+9
+7
+6
+2
+0.3
0
-10
+10
+7
+5
+2
+3.2
0
-8
Activities SBP DBP
Slide 17
KEY LEARNING POINTS
• Proper steps in blood pressure measurement is important to avoid inaccurate readings.• Optimal blood pressure measurement determines management strategies
WO
RK
SH
OP
ON
BP
(BP
ME
AS
UR
EM
EN
T TE
CH
NIQ
UE
& S
KIL
LS)
02.Layout 10/18/10 12:50 PM Page 134
02.Layout 10/18/10 12:50 PM Page 135
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
136
PRE & POST TEST QUESTIONNAIREMULTIPLE CHOICES QUESTIONS (MCQs) (TRUE/FALSE)
TOPIC 2: DIAGNOSIS AND MANAGEMENT OF PRE-HYPERTENSION
1. The following statement(s) is/are true regarding pre-hypertension:A. If left untreated, almost two thirds will progress to develop stage 1 hypertensionB. Younger individuals are associated with a higher rate of progressionC. It tends to cluster with other cardiovascular risk factorsD. Almost a third of BP-related deaths from coronary heart disease occur in pre-hypertensive
individualsE. Pre-hypertensive level of blood pressure itself is an independent cardiovascular risk factor
2. With regards to the management of pre-hypertension, the following statement(s) is/are true:A. All patients should be managed with therapeutic lifestyle modificationB. Patients should be followed up at least once every 2 yearsC. Decisions regarding pharmacological treatment should be based on the individual’s global
cardiovascular riskD. Pharmacological treatment is indicated in pre-hypertensive patients at low cardiovascular riskE. In patients with diabetes mellitus and pre-hypertension, pharmacological treatment is
required if BP is > 130/80 mmHg
TOPIC 3: DIAGNOSIS AND MANAGEMENT OF STAGE 1 HYPERTENSION
1. Madam Y has recently been diagnosed with stage 1 hypertension. She is a heavy smoker and hertotal cholesterol is 6.8 mmol/L. The following statement(s) is/are true regarding her condition andmanagement:A. She has a medium cardiovascular riskB. Her target blood pressure is < 140/90 mmHgC. Pharmacological treatment should commence with combination of 2 drugs at low doseD. β-blocker is recommended for first line therapy for this patientE. Thiazide diuretic is contraindicated in her case
2. The following statement(s) is/are true with regards to the management of stage 1 hypertension:A. In patients without target organ damage, an observational period of 3-6 months on lifestyle
modification is recommendedB. Monotherapy can lower the blood pressure to < 140/90 mmHg in 40-60% of casesC. Increasing the dose of the initial drug is an option if patient shows response but target BP is not
achievedD. Monotherapy should be continued for at least 6 months before a second drug can be addedE. Substituting the drug with another class is recommended when the drug is not tolerated
PR
E-T
ES
T A
ND
PO
ST-
TES
T Q
UE
STI
ON
NA
IRE
(MC
Qs)
02.Layout 10/18/10 12:50 PM Page 136
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
137
TOPIC 4: DIAGNOSIS AND MANAGEMENT OF STAGE 2 HYPERTENSION &RESISTANT HYPERTENSION
1. For patients with stage 2 hypertension, the target blood pressure of < 140/90 mmHg isrecommended if they have: A. History of tobacco smoking B. Diabetes mellitusC. Chronic kidney diseaseD. Central obesityE. Cardiovascular disease
2. Below is/are the recommended antihypertensive combination(s) for patients with stage 2hypertension and heart failure:A. β-blocker + ACEiB. β-blocker + CCBC. CCB + ACEiD. ACEI + diureticE. ARB + diuretic
3. The following statement(s) is/are true with regards to resistant hypertension:A. It is defined when a patient’s BP is > 140/90 mmHg on 3 antihypertensive agents including a
diuretic at near maximal doseB. Non-compliance to medication must be excludedC. The commonest cause is secondary hypertensionD. Excessive salt intake is a contributing factorE. Specialist referral is required in suspected cases of renal artery stenosis
TOPIC 5: DIAGNOSIS AND MANAGEMENT OF STAGE 3 HYPERTENSION
1. A 48-year-old woman is evaluated for hypertension. Physical examination showed BP: 182/86mmHg. She does not give history of headaches. Fundoscopy showed that she has Grade 3Hypertensive retinopathy. Her home blood pressure measurements remain the same results asabove. Which of the following statement(s) is/are true :A. She is having Hypertensive UrgenciesB. Patient can be reassured of her blood pressure readingsC. She needs to be referred to the nearest hospital for initiating antihypertensive agentD. She can be managed as outpatient with just home blood pressure monitoringE. She may need hospital admission if her blood pressure remains elevated after 30 minutes of rest
2. A 56-year-old man was diagnosed with essential hypertension 6 months ago. His blood pressure remained elevated at average 174/110 mmHg. He was taking Tablet Amlodipine 5 mg daily. His blood pressure today in the clinic is 172/112 mmHg. He denied of having anyheadache or blurring of vision. There were no hypertensive retinopathy changes in his eyes. Whichof the following statement(s) is/are most appropriate for the patient at the current situation?A. He must be referred to the hospital today for further evaluation of his blood pressure readingsB. Advice him to continue to comply with his current medicineC. He has Stage 3 HypertensionD. We should ask for symptoms of limb weakness. E. We would order Urine microalbumin test
3. The following statement(s) is/are correct regarding the management of Stage 3 Hypertension:A. Patient’s blood pressure target is < 140/90 mmHg if there is no target organ complicationB. Non-adherence to therapy is an important cause of uncontrolled blood pressureC. Monotherapy is sufficient to get the blood pressure to targetD. Fundoscopy and an ECG evaluation are needed for assessments of their target organ damage
or complicationE. There is no role of therapeutic lifestyle changes for these patients
PR
E-T
ES
T A
ND
PO
ST-
TES
T Q
UE
STI
ON
NA
IRE
(MC
Qs)
02.Layout 10/18/10 12:50 PM Page 137
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
138
TOPIC 6: HYPERTENSION AND DIABETES
1. A 54-year-old man with type 2 diabetes has had intermittent mild headaches for the past onemonth. He is now euglycemic with oral hypoglycemic agents and lifestyle modifications. His oldersister has had hypertension and has been taking antihypertensive medications for several years.Physical exam reveals an afebrile medium size man with a BP of 158/96 mm Hg (average of 2readings), normal and regular peripheral pulses, hard exudates and narrowing of the arterioles onfundoscopic exam, and no carotid bruits. Lungs are clear and neurologic exam is also normal. Hisrecent test result show the following: fasting plasma glucose, 5.8 mmol/L; HbA1c, 6.9%; normalurinalysis; and normal electrocardiogram (ECG).
Which of the following(s) would you consider for treatment of this patient?A. A thiazide-type diureticB. A combination of a β-blocker and thiazide-type diureticC. A combination of a β-blocker and an ACE inhibitorD. A combination of a calcium channel blocker and an ACE inhibitorE. A combination of a thiazide-type diuretic and a ARB
2. In the drug management of hypertension in diabetic patients,A. amlodipine worsens peripheral neuropathyB. atenolol causes hypoglycemia C. hydrochlorothiazide is contraindicated in the presence of proteinuriaD. perindopril prevents cardiovascular eventsE. prazocin reduces glucose metabolism
3. Which of the following statements regarding management of hypertensive patient with type 2diabetes mellitus is/are TRUE?A. When the systolic blood pressure is > 20 mmHg above goal or diastolic blood pressure is > 10
mmHg above goal, monotherapy is recommendedB. Many patients require 3 or more antihypertensive medications to achieve blood pressure goalC. All patients with diabetes and hypertension should be treated with calcium channel blockerD. They need less stringent blood pressure goalE. Pharmacotherapy is indicated in patients with microalbuminuria
TOPIC 7: HYPERTENSION AND METABOLIC SYNDROME
1. Which of the criterion/criteria below is/are TRUE for Metabolic SyndromeA. Waist circumference of > 90 in men and > 80 in womenB. Raised Blood pressure > 130/85 mmHgC. Fasting blood sugar of > 6.1 mmol/LD. Raised Triglyceride and Low HDLE. Raised Triglyceride and Raised LDL
2. In the drug management for patients with Hypertension and Metabolic Syndrome.A. Thiazide Diuretics is recommended as first line agentB. ß-blockers should be avoidedC. ACE Inhibitor is a recommended drug of choiceD. Calcium Channel Blocker should be avoidedE. Combination therapy is considered safe
3. Which of the statement(s) below regarding Metabolic Syndrome is/are TRUEA. It is associated with increased risk of developing cardiovascular diseaseB. It is associated with increased risk of developing diabetes insipidusC. Lifestyle modification is not as important as drug managementD. It requires education for patients to achieve target BP of < 130/80 mmHgE. Weight loss management is crucial in reversing risk of Metabolic Syndrome
PR
E-T
ES
T A
ND
PO
ST-
TES
T Q
UE
STI
ON
NA
IRE
(MC
Qs)
02.Layout 10/18/10 12:50 PM Page 138
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
139
TOPIC 8: HYPERTENSION AND CARDIOVASCULAR DISEASE
1. A 56-year-old man presented with intermittent left pain calf pain worsen on prolong walking. He hasno significant past medical history. His blood pressure was 140/90 mmHg. The left dorsalis pedispulse was weaker than the right side. Which of the following statement(s) is/are correct?A. His risk of stroke is highB. Electrocardiography is an optional investigationC. He should be called back within a week to confirm his status of hypertensionD. Atenolol is an appropriate anti-hypertensiveE. His target blood pressure is < 140/90 mmHg
2. Which of the following scenario(s) is/are correctly paired with the optimal choice of anti-hypertensives given?A. A 60-year-old woman with congestive cardiac failure secondary to prolong uncontrolled
hypertensive: AtenololB. A 50-year-old man with primary stage II hypertension and left ventricular hypertrophy: LosartanC. A 70-year-old man with primary hypertension and significant Q wave in his electrocardiogram at
the anterior chest leads: AmlodipineD. A 45-year-old man with primary hypertension and recent myocardial infarct: PerindoprilE. A 66-year-old woman with uncontrolled hypertension and congestive heart failure NYHA classII
who are already on T. Perindopril 4 mg daily: Metoprolol
3. The following(s) is/are necessary in the assessment of patient presented with symptoms of heartfailure and prolong hypertension:A. Urine proteinB. Heamoglobin levelC. Chest X-rayD. Doppler ultrasound of peripheral arteries in the lower limbE. Serum potassium and sodium
TOPIC 9: HYPERTENSION AND STROKE
1. Ahmad, a 45-year-old businessman presented to the health clinic with left sided body weakness of 1 day duration. His vital signs are as below:BP : 190/110 mmHgPR : 90 beats/minTemp : 36.5˚CRR : 14 breaths/minThe following statement(s) is/are correct regarding Ahmad’s condition:A. Ahmad is categorized under Hypertensive UrgenciesB. Oral Captopril can be given to lower Ahmad’s blood pressureC. Aspirin is recommendedD. He can be treated as an out-patientE. He needs oxygen supplementation for cerebral protection
2. The following statement(s) is/are correct regarding hypertension and stroke:A. Dyslipidaemia is a better predictor of stroke compared to blood pressureB. Drug treatment is recommended in previous history of Transient Ischaemic Attack (TIA)C. In haemorrhagic stroke presented with BP > 180/110 mmHg, immediate reduction of BP is best
avoidedD. Diastolic blood pressure (DBP) is more predictive for strokeE. ß-blockers have been shown to reduce risk and mortality of stroke
PR
E-T
ES
T A
ND
PO
ST-
TES
T Q
UE
STI
ON
NA
IRE
(MC
Qs)
02.Layout 10/18/10 12:50 PM Page 139
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
140
3. Mr. Tan a 58-year-old pensioner had history of ischaemic stroke 5 years ago. His current medicationsare Aspirin 150 mg OD and Hydrochlorothiazide 25mg OD. The following statement(s) is/are correct:A. CCB provides better protection than Thiazide Diuretic regarding secondary prevention B. It is recommended to withhold his Hydrochlorothiazide if his blood pressure ranges from
110-120/70-80 mmHgC. Perindopril is the preferred choiceD. His target LDL level is < 3.4 mmol/LE. His target blood pressure control is < 140/90 mmHg
4. The following statement(s) is/are correct regarding Stroke:A. In Asia Pacific region, about 2/3 of strokes attributed to hypertensionB. Combination of an ACE-Inhibitor and diuretic has been shown to reduce recurrent stroke.C. Treatment with aspirin alone is sufficientD. In primary prevention, the risk of stroke is significantly reduced with 10 mmHg reduction of
systolic blood pressureE. In severe hypertensive with acute stroke, blood pressure lowering to < 160/90 mmHg is
mandatory
TOPIC 10: HYPERTENSION IN THE ELDERLY
1. Based on current evidence, the following class(es) of drugs has / have been shown to reducecardiovascular events in the elderly:A. Calcium channel blockersB. Ace inhibitorsC. β-blockersD. DiureticsE. α-blockers
2. When prescribing antihypertensive agents in the elderly, the following rule(s) is/are important:A. Start with low doseB. Go slow on increasing the doseC. Combination preparation is encouragedD. The target BP is below 130/80 mm HgE. In patients with marked systolic hypertension, reducing SBP below 160 mmHg is initially
acceptable
3. In patients with postural hypertension, the following BP should be used as a guide to treatmentdecisions:A. Standing BPB. Sitting BPC. Lying BPD. Supine BPE. Ambulatory BP
TOPIC 11: HYPERTENSION IN PREGNANCY
1. Which of the following(s) is/are the risk factor(s) for developing high blood pressure in pregnancy?A. First pregnancyB. Previous history of hypertension during pregnancyC. Twin pregnancy D. Diabetes MellitusE. Poor weight gain
PR
E-T
ES
T A
ND
PO
ST-
TES
T Q
UE
STI
ON
NA
IRE
(MC
Qs)
02.Layout 10/18/10 12:50 PM Page 140
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
141
2. What is/are the complication(s) of hypertension in pregnancy?A. Fits B. StrokeC. Placenta accretaD. StillbornE. Disseminated intravascular coagulopathy
3. Which of the following(s) is/are the sign(s) of pre-eclampsia?A. Sudden increase in weight (> 1 kg per week)B. Polyuria C. Epigastric pain D. Visual disturbance such as blurred visionE. Nausea and vomiting
TOPIC 12: HYPERTENSION AND ORAL CONTRACEPTIVE PILLS
1. The following statement(s) is/are true regarding hypertension and oral contraceptives:A. Baseline blood pressure is essential before initiating combined oral contraceptive (COC)B. Progestrogene only pills (POP) are known to raise blood pressureC. Incidence of hypertension is reported to be higher in woman taking COCD. Women who develop hypertension while using COC are advisable to continue using COC
provided their blood pressure is monitored regularlyE. Low dose COC is a recommended alternative for patients with hypertension who wish to
continue oral contraception
2. The following contraceptive method(s) is/are known to raise blood pressure:A. Combined oral contraceptive (COC)B. Intrauterine Devices (IUDs)C. Progesterone only pills (POP)D. MirenaE. Low dose COC
TOPIC 13: HYPERTENSION AND HORMONE REPLACEMENT THERAPY
1. In the management of a hypertensive post-menopausal women on hormone replacement therapy: A. The decision to continue or discontinue HRT in these patients should be individualisedB. Physician should be aware that the use of HRT increased the risk of recurrent cardiovascular
eventsC. Monitoring of every three months is recommended if BP is uncontrolledD. Cardiovascular risk stratification should be done annually E. Pap smear should be done bi-annually up to 65 years of age
2. A hypertensive woman on hormone replacement therapy is at risk for:A. Breast cancerB. Colorectal cancerC. Venous thromboembolismD. Osteoporosis E. Gall-bladder disease
PR
E-T
ES
T A
ND
PO
ST-
TES
T Q
UE
STI
ON
NA
IRE
(MC
Qs)
02.Layout 10/18/10 12:50 PM Page 141
MA
NA
GE
ME
NT
OF
HY
PE
RT
EN
SIO
N (
3rdE
dit
ion
)T
RA
ININ
G M
OD
UL
E F
OR
HE
ALT
H C
AR
E P
RO
VID
ER
S
142
PRE & POST TEST QUESTIONNAIREMULTIPLE CHOICES QUESTIONS (MCQs) (TRUE/FALSE)
ANSWER
TOPIC 2: DIAGNOSISAND MANAGEMENTOF PRE-HYPERTENSION
1. A. TB. FC. TD. TE. T
2. A. TB. FC. TD. FE. T
TOPIC 3: DIAGNOSISAND MANAGEMENTOF STAGE 1HYPERTENSION
1. A. TB. TC. FD. FE. F
2. A. TB. TC. TD. FE. T
TOPIC 4: DIAGNOSISAND MANAGEMENTOF STAGE 2HYPERTENSION &RESISTANTHYPERTENSION
1. A. TB. FC. TD. TE. T
2. A. TB. FC. FD. TE. T
3. A. TB. TC. FD. TE. T
TOPIC 5: DIAGNOSISAND MANAGEMENTOF STAGE 3HYPERTENSION
1. A. TB. FC. FD. FE. T
2. A. FB. FC. TD. TE. T
TOPIC 6:HYPERTENSION ANDDIABETES
1. A. FB. FC. FD. TE. T
2. A. FB. FC. FD. TE. F
3. A. FB. TC. FD. FE. T
TOPIC 7:HYPERTENSION ANDMETABOLICSYNDROME
1. A. TB. TC. TD. TE. F
2. A. FB. TC. FD. TE. T
3. A. TB. FC. FD. TE. T
TOPIC 8:HYPERTENSION ANDCARDIOVASCULARDISEASE
1. A. TB. FC. FD. FE. F
2. A. FB. TC. FD. TE. F
3. A. TB. TC. TD. FE. T
TOPIC 9:HYPERTENSION ANDSTROKE
1. A. FB. TC. FD. FE. T
2. A. FB. TC. TD. FE. T
3. A. TB. FC. TD. FE. F
4. A. TB. TC. FD. TE. F
TOPIC 10:HYPERTENSION INTHE ELDERLY
1. A. TB. TC. TD. TE. F
2. A. TB. TC. FD. FE. T
3. A. TB. FC. FD. TE. F
TOPIC 11:HYPERTENSION INPREGNANCY
1. A. TB. TC. TD. TE. F
2. A. TB. TC. FD. TE. T
3. A. TB. FC. TD. TE. T
TOPIC 12:HYPERTENSION ANDOCP
1. A. TB. FC. TD. FE. T
2. A. TB. FC. FD. FE. F
TOPIC 13:HYPERTENSION ANDHORMONEREPLACEMENTTHERAPY
1. A. TB. TC. FD. TE. F
2. A. TB. FC. TD. FE. F
PR
E-T
ES
T A
ND
PO
ST-
TES
T Q
UE
STI
ON
NA
IRE
(MC
Qs)
02.Layout 10/18/10 12:50 PM Page 142